

# Differences in mitochondrial activity trigger cell competition during early mouse development

Ana Lima<sup>1,2,#</sup>, Gabriele Lubatti<sup>3,4,5,#</sup>, Jörg Burgstaller<sup>6</sup>, Di Hu<sup>7</sup>, Alistair Green<sup>8</sup>, Aida Di Gregorio<sup>1</sup>, Tamzin Zawadzki<sup>1</sup>, Barbara Pernaute<sup>1,9</sup>, Elmir Mahammadov<sup>3,4,5</sup>, Marian Dore<sup>2</sup>, Juan Miguel Sanchez<sup>1</sup>, Sarah Bowling<sup>1</sup>, Margarida Sancho<sup>1</sup>, Mohammad Karimi<sup>2</sup>, David Carling<sup>2</sup>, Nick Jones<sup>8</sup>, Shankar Srinivas<sup>7</sup>, Antonio Scialdone<sup>3,4,5\*</sup> and Tristan A. Rodriguez<sup>1,\*</sup>

<sup>1</sup> National Heart and Lung Institute, Imperial College London, UK

<sup>2</sup> MRC London Institute of Medical Sciences (LMS), Institute of Clinical Sciences, Imperial College London, UK

<sup>3</sup> Institute of Epigenetics and Stem Cells, Helmholtz Zentrum München, Munich, Germany

<sup>4</sup> Institute of Functional Epigenetics, Helmholtz Zentrum München, Neuherberg, Germany

<sup>5</sup> Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany

<sup>6</sup> Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria

<sup>7</sup> Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK

<sup>8</sup> Department of Mathematics, Imperial College London, UK.

<sup>9</sup> Current address: Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Dr. Aiguader 88, Barcelona 08003, Spain

# Both these authors contributed equally

\* Authors for correspondence: [antonio.scialdone@helmholtz-muenchen.de](mailto:antonio.scialdone@helmholtz-muenchen.de);

[tristan.rodriquez@imperial.ac.uk](mailto:tristan.rodriquez@imperial.ac.uk)

## Summary

Cell competition is emerging as a quality control mechanism that eliminates unfit cells in a wide range of settings from development to the adult. However, the nature of the cells normally eliminated by cell competition and what triggers their elimination remains poorly understood. Here we have performed single cell transcriptional profiling of early mouse embryos and find that the cells eliminated show the hallmarks of cell competition, are mis-patterned and have mitochondrial defects. We demonstrate that mitochondrial defects are common to a range of different loser cell types and that manipulating mitochondrial function is sufficient to trigger competition. Importantly, we show that in the embryo loser epiblast cells display mitochondrial DNA mutations and that even small changes in mitochondrial DNA sequence can influence the competitive ability of the cell. Our results therefore suggest that cell competition is a purifying selection that optimises metabolic output prior to gastrulation.

Running title: Cell competition and mitochondrial selection

Keywords: mitochondria, mtDNA, mouse development, cell competition, purifying selection

## 1 Introduction

2 During the early stages of mammalian development, the cellular and molecular landscape is  
3 profoundly remodelled. As embryonic cells approach gastrulation, when the precursors of all  
4 embryonic tissues are specified, they need to rewire the transcriptional, epigenetic, metabolic and  
5 signalling networks that govern cell identity (Kojima et al., 2014). These changes are accompanied  
6 by a marked acceleration in the proliferation rate (Snow, 1977) and need to be orchestrated with  
7 the different morphogenetic processes that re-shape the embryo (reviewed in (Stower and  
8 Srinivas, 2018). The scale of this remodelling creates the potential for the emergence of abnormal  
9 cells that need to be removed to prevent them from contributing to the soma or germline during  
10 development. This requirement implies that there must be stringent cell fitness quality control  
11 mechanisms acting around the time of gastrulation. One such control has been postulated to be  
12 cell competition, a fitness sensing mechanism eliminating cells that, although viable, are less fit  
13 than their neighbours (reviewed in (Bowling et al., 2019; Diaz-Diaz and Torres, 2019; Madan et  
14 al., 2018). During cell competition, the cells that are eliminated are generically termed losers, while  
15 the fitter cells that survive are referred to as winners.

16 Cell competition has been primarily studied in *Drosophila*, where it was first described in the  
17 imaginal wing disc (Morata and Ripoll, 1975). Since then, it has also been found to be conserved  
18 in mammals. For example, in the mouse embryo between E5.5 and E6.5 cell competition has  
19 been proposed to eliminate less-fit cells from the epiblast, the pluripotent tissue that generates the  
20 three primary germ-layers (Claveria et al., 2013; Sancho et al., 2013). Importantly, in the time-  
21 window when cell competition acts, about one third of epiblast cells are eliminated by apoptosis  
22 (Bowling et al., 2018). These cells are marked by a loss of mTOR signalling, a read-out of loser  
23 status during cell competition *in vitro* (Bowling et al., 2018). This suggests that cell competition is  
24 the primary cause of this cell elimination. Other markers of those cells eliminated in the early post-  
25 implantation embryo have been identified as relative low c-MYC expression, high P53 expression  
26 or elevated levels of ERK phosphorylation (Bowling et al., 2018; Claveria et al., 2013; Diaz-Diaz  
27 et al., 2017; Sancho et al., 2013), that together could be considered as a cell competition signature.

28 In spite of the advance that identifying these markers signifies, we still do not know what  
29 overarching cellular and molecular features define the cells eliminated by cell competition in  
30 mouse. Using embryonic stem cells (ESCs) and embryo chimeras we have shown that mis-  
31 patterned cells, autophagy deficient cells and karyotypically abnormal cells are all eliminated upon  
32 differentiation by cell competition (Bowling et al., 2018; Sancho et al., 2013). Cell competition has  
33 also been shown to eliminate pluripotent cells that differentiate precociously (Diaz-Diaz et al.,  
34 2017) or that are not properly specified (Hashimoto and Sasaki, 2019). Therefore, a variety of  
35 different defective cell types can be eliminated by cell competition, but which is the underlying  
36 cause for their elimination remains poorly understood.

37 Mitochondria, with their diverse cellular functions ranging from determining the bioenergetic output  
38 of the cell to regulating its apoptotic response, are strong candidates for determining competitive  
39 cell fitness. During early mouse development mitochondria undergo profound changes in their  
40 shape and activity (reviewed in (Lima et al., 2018)). In the pre-implantation embryo mitochondria  
41 are rounded, fragmented and contain sparse cristae, but upon implantation they fuse to form  
42 complex networks with mature cristae (Zhou et al., 2012). The mode of replication of the  
43 mitochondrial genome (mtDNA), that encodes for vital components of the bioenergetic machinery,  
44 also changes during early mouse development. After fertilization, mtDNA replication ceases and  
45 its copy number per cell decreases with every division until post-implantation stages, when mtDNA  
46 replication resumes (reviewed in (Lima et al., 2018)). However, as the mutation rate of mtDNA is  
47 significantly higher than that of nuclear DNA (Allio et al., 2017; Khrapko et al., 1997) this increased  
48 replication most likely leads to an increased mutation load. A number of mechanisms have been  
49 proposed to reduce this mutation load, such as the bottleneck effect, purifying selection or biased  
50 segregation of mtDNA haplotypes (Burgstaller et al., 2014; Johnston et al., 2015; Latorre-Pellicer  
51 et al., 2019; Lee et al., 2012; Sharpley et al., 2012; Zhang et al., 2018). However, despite these  
52 mechanisms, inheritable mtDNA based diseases are reported with a prevalence of 5-15 cases per  
53 100,000 individuals (Burgstaller et al., 2015; Gorman et al., 2016), highlighting both the  
54 importance and limitations of these selection mechanisms.

55 To understand the nature of the cells eliminated during early mouse post-implantation  
56 development we have analysed their transcriptional profile by single-cell RNA sequencing.  
57 Importantly, we have found that these cells share a cell competition signature. Analysis of the  
58 pathways mis-regulated in the cells eliminated identified mitochondrial dysfunction as a common  
59 feature. Furthermore, we demonstrate that manipulating mitochondrial activity either by disrupting  
60 mitochondrial dynamics or by introducing small mtDNA changes is sufficient to trigger cell  
61 competition during early mouse development. These results therefore pinpoint mitochondrial  
62 performance as a key cellular feature that determines the competitive ability of embryonic cells.

63

## 64 **Results**

### 65 **Cells eliminated in the early mouse embryo have a distinct transcriptional profile**

66 We have previously shown that in the early post-implantation mouse embryo about 35% of epiblast  
67 cells are eliminated and that these cells are marked by low mTOR signalling (Bowling et al., 2018).  
68 However, we currently do not understand the characteristics of these cells or what triggers their  
69 elimination. To answer these questions, we have analysed their transcriptional profile by single  
70 cell RNA sequencing (scRNA-seq). To ensure we can capture the eliminated cells, as we have  
71 done before (Bowling et al., 2018), we isolated embryos at E5.5 and cultured them for 16 hours in  
72 the presence of a caspase inhibitors (CI) or vehicle (DMSO) (Figure 1A and Figure S1A).

73 Unsupervised clustering of the scRNA-seq data revealed five clusters: two corresponding to extra-  
74 embryonic tissues (visceral endoderm and extra-embryonic ectoderm) and three that expressed  
75 epiblast marker genes (Figure 1B-C and Figure S1B-D). Interestingly, cells from CI- and DMSO-  
76 treated embryos are unequally distributed across the three epiblast clusters. In particular, one of  
77 these clusters (cluster 4) is only composed of cells from CI-treated embryos (Figure 1D-E). To  
78 establish the relationship between these epiblast clusters we computed a diffusion map (Angerer  
79 et al., 2016). For this, we selected only cells captured from CI-treated embryos, to eliminate  
80 possible confounding effects due to the caspase inhibitor (Figure 2A). However, when all epiblast  
81 cells are considered, the results remain unchanged (Figure S2A-C). This analysis identified a  
82 trajectory between the three epiblast clusters, with those cells unique to CI-treated embryos falling  
83 at one extreme end of the trajectory (corresponding to cluster 4; Figure 2A) and with those cells  
84 present in both DMSO and CI-treated embryos at the other (corresponding to cluster 1; Figure 2A  
85 and Figure S2A-C).

86 To further define the identity of the epiblast cells of CI-treated embryos we analysed the genes  
87 differentially expressed along the trajectory (see Methods and Figure S2D) using Ingenuity  
88 Pathway Analysis (IPA) to characterize gene signatures (Kramer et al., 2014). Importantly, we  
89 found that these differentially expressed genes fell under molecular and cellular function  
90 categories associated with cell death and survival, protein synthesis and nucleic acids (Figure 2B).  
91 Analysis of the factors with enriched targets within the genes differentially expressed along the  
92 trajectory revealed RICTOR (an mTOR component), TLE3, MYC, MYCN, P53 and IGFR (that is  
93 upstream of mTOR) as the top upstream regulators (Figure 2C). Breaking down the differentially  
94 expressed genes into those down-regulated or up-regulated along the winner-to loser trajectory  
95 revealed that the targets of RICTOR, MYC, MYCN and IGFR primarily fell within the down-  
96 regulated genes (Supplementary Tables 1 and 2). P53 activated targets were preferentially up-  
97 regulated and P53 repressed targets were preferentially down-regulated (Figure S2E-F).  
98 Moreover, genes related to protein synthesis were primarily found to be downregulated.

99 The first identified trigger of cell competition were differences in protein synthesis (Morata and  
100 Ripoll, 1975), therefore the observation that the genes differentially expressed along the trajectory  
101 fall into cell death and protein synthesis categories, as well as being mTOR, MYC and P53 targets  
102 strongly suggests that cells at each end of the trajectory are the winners and losers of cell  
103 competition. For this reason, we hereafter refer to those epiblast cells unique to CI-treated  
104 embryos as “loser” epiblast cells and to those at the opposite end of the trajectory as the “winner”  
105 epiblast cells. Those cells lying between these two populations on the trajectory are considered  
106 “intermediate”. Using this knowledge we can define a diffusion pseudotime (dpt) coordinate  
107 (Haghverdi et al., 2016) originating in the “winner” cluster that tracks the position of cells along the

108 trajectory and that can be interpreted as a “losing score”, i.e., it quantifies how strong the signature  
109 of the “losing” state is in the transcriptome of a cell (see Figure 2D-E).

### 110 **Loser cells show a signature of mis-patterning**

111 The most notable change that embryonic cells undergo during early development is the onset of  
112 differentiation. During this process cells transit from naïve to primed pluripotency and then undergo  
113 germ layer specification (Nichols and Smith, 2009). For this reason, we analysed the expression  
114 of pluripotency and differentiation markers as a function of the losing score of epiblast cells (Figure  
115 2F). We found that loser cells (with high losing scores) have lower levels of expression of genes  
116 such as *Fgf5* and *Tdgf1*, which are characteristic of the primed pluripotency state. In contrast to  
117 this, they displayed high levels of expression of some naïve pluripotency markers such as *Klf4*  
118 and *Klf5*, but not of others, such as *Rex1* (*Zfp42*). Analysis of lineage specific markers revealed a  
119 complex pattern. For example, some loser cells showed high expression of the endoderm marker  
120 *Sox17*, but not of *Gata6*. Something similar was observed for neuroectoderm markers, whereby  
121 loser cells showed significantly higher expression of *Neurod1* than winner cells, but comparable  
122 levels of *Sox1*.

123 Plotting the levels of markers of naïve pluripotency and germ layers against each other for single  
124 cells revealed that some loser epiblast cells expressed higher levels of both naïve pluripotency  
125 and germ-layer markers than normal epiblast cells (Figure 2G). Together, these data suggest that  
126 loser epiblast cells represent a generic mis-patterned state, rather than precocious or delayed  
127 differentiation.

### 128 **Loser cells are characterised by defects in mitochondrial function**

129 We next analysed using IPA the cellular pathways mis-regulated in loser epiblast cells and found  
130 that the top two pathways (mitochondrial dysfunction and oxidative phosphorylation) are related  
131 to mitochondrial function (Figure 3A). Detailed inspection of the oxidative phosphorylation  
132 signature in loser versus normal epiblast cells indicated that 92.6% of the genes in this pathway  
133 were mis-regulated (Figure 3A), including the majority of genes encoding proteins of the five  
134 complexes (Complexes I to V) of the electron transport chain (ETC)(Figure 3B), that were down-  
135 regulated along the winner-to-loser trajectory (Supplementary Table 1). For example, we found a  
136 down-regulation along the winner to loser trajectory of the mitochondrial DNA encoded *mt-Nd3*  
137 and *mt-Atp6* (Figure 3C), of regulators of mitochondrial dynamics such as *Opa1*, as well as of  
138 genes involved in mitochondrial membrane and cristae organisation such as *Samm50*, (Figure  
139 3C).

140 A recent body of evidence has revealed that stress responses, such as the integrated stress  
141 response (ISR) or the closely related unfolded protein response (UPR), when triggered in cells  
142 with impaired mitochondrial function prompt a transcriptional program to restore cellular

143 homeostasis (Melber and Haynes, 2018; Munch, 2018; Topf et al., 2016). We observed that loser  
144 epiblast cells displayed a characteristic UPR-ISR signature (Figure S3A-C) (Mouchiroud et al.,  
145 2013; Nargund et al., 2012; Quiros et al., 2016; Zhao et al., 2002) and key regulators of this  
146 response, such as *Atf4*, *Ddit3*, *Nrf2* and *Foxo3* were all up-regulated in these cells (Figure S3D).  
147 Similarly, *Sesn2*, a target of p53 that controls mTOR activity (Saveljeva et al., 2016), was also up-  
148 regulated in loser cells (Figure S3D). These findings support the possibility that loser epiblast  
149 cells present mitochondrial defects, leading to the activation of a stress response in an attempt to  
150 restore cellular homeostasis (Yun and Finkel, 2014).

151 To validate the significance of the mitochondrial defects observed, we did two things. First, we  
152 asked if the changes observed at the mRNA level are also reflected at the protein level. We  
153 observed that in CI-treated embryos, loser cells that persist and are marked by low mTOR activity  
154 (Bowling et al., 2018), also show significantly lower OPA1 levels (Figure 3D-F). This finding is in  
155 agreement with the observation that OPA1 levels are decreased during mitochondrial stress  
156 (Quiros et al., 2017). We also found that DMSO-treated embryos showed strong DDIT3 staining  
157 (an UPR-ISR marker) in the dying cells that accumulate in the proamniotic cavity, and that in CI-  
158 treated embryos, DDIT3 expression was up-regulated in a proportion of epiblast cells (Figure S3E-  
159 G). The second thing we did to validate the importance of the mitochondrial defects observed was  
160 to study in loser epiblast cells the mitochondrial membrane potential ( $\Delta\psi_m$ ), an indication of  
161 mitochondrial health. We observed that while the cells of DMSO-treated embryos showed a high  
162  $\Delta\psi_m$  that fell within a narrow range, in CI-treated embryos the proportion of cells with a low  $\Delta\psi_m$   
163 significantly increased (Figure 3D and 3G-H). Together, these results suggest that loser epiblast  
164 cells have impaired mitochondrial activity that triggers a stress response.

### 165 **Mitochondrial dysfunction is common to different types of loser cells**

166 The above data indicate that loser epiblast cells are mis-patterned and show mitochondrial  
167 defects. To address if mitochondrial defects are a common feature of mis-patterned cells we  
168 analysed ESCs that are defective for BMP signalling (*Bmpr1a*<sup>-/-</sup>), as these are abnormally  
169 patterned (Di-Gregorio et al., 2007) and eliminated by cell competition (Sancho et al., 2013). In  
170 parallel, to determine if mitochondrial defects are present in other loser cells eliminated by cell  
171 competition, we also studied tetraploid cells (4n) (Sancho et al., 2013). We first carried out a mass  
172 spectrometry analysis using the Metabolon platform and found that metabolites and intermediates  
173 of the TCA cycle, such as malate, fumarate, glutamate and  $\alpha$ -ketoglutarate are depleted in both  
174 *Bmpr1a*<sup>-/-</sup> and 4n ESCs in differentiation culture conditions (Figure 4A). Next, we performed an  
175 extracellular flux Seahorse analysis of *Bmpr1a*<sup>-/-</sup> ESCs to measure their glycolytic and oxidative  
176 phosphorylation (OXPHOS) rates. We observed that when these cells are maintained in  
177 pluripotency culture conditions, that are not permissive for cell competition (Sancho *et al.*, 2013),  
178 they showed a similar glycolytic activity, but a higher OXPHOS rate than control cells (Figure S4A-

179 D). In contrast, when *Bmpr1a*<sup>-/-</sup> cells are induced to differentiate, this phenotype is reversed, with  
180 mutant cells showing lower ATP generated through OXPHOS and a higher glycolytic capacity than  
181 controls (Figure 4B-E; Figure S4E-F). This suggests that upon differentiation *Bmpr1a*<sup>-/-</sup> cells are  
182 unable to sustain proper OXPHOS activity.

183 To further test the possibility that defective ESCs have impaired mitochondrial function, we  
184 assessed their  $\Delta\psi_m$ . We found that whilst *Bmpr1a*<sup>-/-</sup> and 4n cells had a similar  $\Delta\psi_m$  to control cells  
185 in pluripotency conditions (Figure S4G-H), upon differentiation both these cell types presented a  
186 loss of  $\Delta\psi_m$ , irrespective of whether they were separate or co-cultured with wild-type cells (Figure  
187 4F-G). This reduction in  $\Delta\psi_m$  is unlikely to be due to excessive mitochondrial reactive oxygen  
188 species (ROS) production or to a lower mitochondrial mass within mutant cells since, as for  
189 example, *Bmpr1a*<sup>-/-</sup> cells have lower ROS levels and similar TOMM20 and mt-CO1 expression as  
190 control cells (Figure 4H-J; Figure S4I). The fact that the loss of  $\Delta\psi_m$  and lower OXPHOS activity  
191 can be observed even when loser cells are cultured separately, suggests that the mitochondrial  
192 dysfunction phenotype is an inherent property of loser cells and not a response to them being out-  
193 competed. These results also indicate that the mitochondrial defects are directly linked to the  
194 emergence of the loser status: in conditions that are not permissive for cell competition  
195 (pluripotency) mutant cells do not show defective mitochondrial function, but when they are  
196 switched to differentiation conditions that allow for cell competition, they display impaired  
197 mitochondrial function.

198 To further explore the relationship between mitochondrial activity and the competitive ability of the  
199 cell, we analysed the  $\Delta\psi_m$  of BMP defective cells that are null for p53 (*Bmpr1a*<sup>-/-</sup>; *p53*<sup>-/-</sup> ESCs), as  
200 these are not eliminated by wild-type cells (Bowling et al., 2018). Remarkably, we observed that  
201 mutating *p53* in *Bmpr1a*<sup>-/-</sup> cells not only rescues the loss of  $\Delta\psi_m$  of these cells, but also causes  
202 hyperpolarisation of their mitochondria (Figure 4K). These results strongly support a pivotal role  
203 for mitochondrial activity in cell competition.

## 204 **Impaired mitochondrial function is sufficient to trigger cell competition**

205 The mitochondrial defects observed in loser cells led us to ask if disrupting mitochondrial activity  
206 alone is sufficient to trigger cell competition. During the onset of differentiation, mitochondria go  
207 from having a fragmented shape to fusing and forming complex networks (reviewed in (Lima et  
208 al., 2018)). We therefore tested if disrupting mitochondrial dynamics induces cell competition.  
209 MFN1 and MFN2 regulate mitochondrial fusion and DRP1 controls their fission (Chen et al., 2003;  
210 Prudent and McBride, 2017; Smirnova et al., 2001). We generated *Drp1*<sup>-/-</sup> ESCs, that show hyper-  
211 elongated mitochondria, and *Mfn2*<sup>-/-</sup> ESCs, that have enlarged globular mitochondria (Figure 5A).  
212 Analysis of the *Drp1* mutant cells showed that although they did not grow significantly slower than  
213 wild-type cells when cultured separately in differentiation inducing conditions, they were out-



214 competed by wild-type cells in co-culture (Figure 5B). In contrast to this, we observed that *Mfn2*<sup>-/-</sup>  
215 ESCs displayed very poor growth upon differentiation (data not shown). For this reason, we tested  
216 their competitive ability in pluripotency conditions, that we have previously found not to induce the  
217 out-competition of *Bmpr1a*<sup>-/-</sup> or 4n cells (Sancho et al., 2013). Interestingly, we found that although  
218 *Mfn2*<sup>-/-</sup> cells grow similarly to wild-type cells in separate cultures, they were out-competed in co-  
219 culture (Figure 5C). The observation that disrupting mitochondrial dynamics can induce cell  
220 competition even in pluripotency culture conditions, suggests that mitochondrial activity is a  
221 dominant parameter determining the competitive ability of the cell.

## 222 **Loser epiblast cells accumulate mtDNA mutations**

223 There is strong evidence for selection against aberrant mitochondrial function induced by  
224 deleterious mtDNA mutations in mammals (Fan et al., 2008; Freyer et al., 2012; Kauppila et al.,  
225 2016; Sharpley et al., 2012; Stewart et al., 2008). Given that we observe that cell competition  
226 selects against cells with impaired mitochondrial function, we asked if cell competition could be  
227 reducing mtDNA heteroplasmy (frequency of different mtDNA variants) during mouse  
228 development. It has been recently shown that scRNA-seq can be used to reliably identify mtDNA  
229 variants, although with a lower statistical power compared to more direct approaches, like mtDNA  
230 sequencing (Ludwig et al., 2019). We therefore tested if mtDNA heteroplasmy is present in our  
231 scRNA-seq data and whether this is associated with the losing score of a cell. Our analysis  
232 revealed that the frequency of specific mtDNA polymorphisms increased with the losing score of  
233 epiblast cells (Figure 6A), and such mtDNA changes occurred within *mt-Rnr1* and *mt-Rnr2* (Figure  
234 6B-H and Figure S5A-E). Moreover, these changes were not dependant on the litter from which  
235 the embryo came from (Figure S5F-K). The mutations we detected in *mt-Rnr1* and *mt-Rnr2*  
236 strongly co-occurred in the same cell, with those closest together having the highest probability of  
237 co-existing (Figure 6I and Figure S5L). This is suggestive of mtDNA replication errors that could  
238 be 'scarring' the mtDNA, disrupting the function of *mt-Rnr1* (12S rRNA) and *mt-Rnr2* (16S rRNA)  
239 and causing the loser phenotype. Importantly, the presence of these specific mtDNA mutations in  
240 the loser cells suggests that cell competition is contributing to the elimination of deleterious mtDNA  
241 mutations during early mouse development.

## 242 **Changes in mtDNA sequence can determine the competitive ability of a cell**

243 To explore this possibility further we analysed if alterations in mtDNA can induce cell competition  
244 by testing the competitive ability of ESCs with non-pathological differences in mtDNA sequence.  
245 For this we compared the relative competitive ability of ESCs that shared the same nuclear  
246 genome background but differed in their mitochondrial genomes by a small number of non-  
247 pathological sequence changes. We derived ESCs from hybrid mouse strains that we had  
248 previously engineered to have a common nuclear C57BL/6N background, but mtDNAs from

249 different wild-caught mice (Burgstaller et al., 2014). Each wild-derived mtDNA variant (or  
250 haplotype) contains a specific number of single nucleotide polymorphisms (SNPs) that lead to a  
251 small number of amino acid changes when compared to the C57BL/6N mtDNA haplotype.  
252 Furthermore, these haplotypes (BG, HB and ST) can be ranked according to their genetic distance  
253 from the C57BL/6N mtDNA (Figures 7A and S6A). Characterization of the isolated ESCs revealed  
254 that they have a range of heteroplasmy (mix of wild-derived and C57BL/6N mtDNAs) that is stable  
255 over several passages (Figure S6B). Importantly, these different mtDNA haplotypes and different  
256 levels of heteroplasmy do not alter cell size, cell granularity, mitochondrial mass or mitochondrial  
257 dynamics, nor do they substantially impact the cell's  $\Delta\psi_m$  (Figure S6C-F).

258 When we tested the competitive ability of these mtDNA ESCs we observed that cells carrying the  
259 mtDNAs that are most distant from the C57BL/6N mtDNA, such as the HB(100%), the HB(24%)  
260 and the ST(46%) ESCs could all out-compete the C57BL/6N line (Figure 7B-C and S6G).  
261 Similarly, when we tested the HB(24%) line against the BG(99%) or the BG(95%) lines (that have  
262 mtDNAs more closely related to the C57BL/6N mtDNA), we found that cells with the HB haplotype  
263 could also out-compete these ESCs (Figure 7D and S6H). In contrast, we observed that the  
264 HB(24%) ESCs were unable to out-compete either their homoplasmic counterparts, HB(100%),  
265 or the ST(46%) cells that carry the most distant mtDNA from C57BL/6N (Figure 7E and S6I).  
266 These results tell us three things. First, that non-pathological differences in mtDNA sequence can  
267 trigger cell competition. Second, that a competitive advantage can be conferred by only a small  
268 proportion of mtDNA content, as indicated by our finding that HB(24%) behave as winners. Finally,  
269 these findings suggest that the phylogenetic proximity between mtDNA variants can potentially  
270 determine their competitive cell fitness.

271 To characterise the mode of competition between different mtDNA cells we focussed on the  
272 HB(24%) and the BG(95%) ESCs. Analysis of these cell lines revealed that specifically when co-  
273 cultured, the BG(95%) cells display high levels of apoptosis (Figure 7F), indicating that their out-  
274 competition is through their elimination. To gain further insight we performed bulk RNA-seq of  
275 these cells in separate and co-culture conditions (Figure S6J) and analysed the differentially  
276 expressed genes by gene-set enrichment analysis (GSEA). We found that in separate culture the  
277 most notable features that distinguish BG(95%) from HB(24%) cells were a down-regulation of  
278 genes involved in oxidative phosphorylation and an up-regulation of those associated with  
279 cytokine activity (Figure 7G). Interestingly, in the co-culture condition, in addition to these  
280 signatures, BG(95%) cells revealed a down-regulation in signature markers of MYC activity and  
281 mTOR signalling (Figure 7H), whose downregulation are known read-outs of a loser status during  
282 cell competition in the embryo (Bowling et al., 2018; Claveria et al., 2013; Sancho et al.,  
283 2013)(Figure 2C). These results suggest that the elimination of loser mtDNA cells occurs through  
284 the same mechanism as the out-competition of defective cells in the embryo (Figure 7I).

285 The finding that the genes down-regulated in BG(95%) cells when co-cultured with HB(24%) cells  
286 fell under functional categories relating to mitochondrial function (Figure S7A) led us to analyse  
287 the degree of overlap between these genes and the genes differentially expressed along the  
288 winner-to-loser trajectory in the embryo. We observed a significant overlap in down-regulated  
289 genes (Figure S7B), as well as in the functional components that these genes can be categorised  
290 into (Figure S7C). This further highlights the importance of relative mitochondrial activity for  
291 determining the competitive ability of embryonic cells.

## 292 Discussion

293 The emerging role of cell competition as a regulator of cell fitness in a wide range of cellular  
294 contexts, from the developing embryo to the ageing tissue (reviewed in (Bowling et al., 2019; Diaz-  
295 Diaz and Torres, 2019; Madan et al., 2018), has highlighted the importance of understanding what  
296 cell types are normally eliminated by this process. With the aim of understanding this question,  
297 we have analysed the transcriptional identity of the cells eliminated in the early mouse embryo.  
298 We have found not only that they present a cell competition signature, but also that they are mis-  
299 patterned and marked by impaired mitochondrial function. Starting from these results, we  
300 leveraged *in vitro* models of cell competition to show that: (i) mitochondrial function is impaired in  
301 loser cells eliminated by cell competition, and (ii) that differences in mitochondrial activity are  
302 sufficient to trigger cell competition in ESCs. Overall, this points to mitochondrial performance as  
303 a key determinant of the competitive ability of cells during early mammalian embryonic  
304 development. One implication of our findings is that a range of different types of defect, such as  
305 mis-patterning, karyotypic abnormalities or mtDNA mutations, all lead to dysfunctional  
306 mitochondria at the onset of differentiation and that ultimately it is their impaired mitochondrial  
307 function that triggers cell competition, inducing their elimination (Figure 7I).

308 It is well known that the successful development of the embryo can be influenced by the quality of  
309 its mitochondrial pool (reviewed in (Lima et al., 2018)). Moreover, divergence from normal  
310 mitochondrial function during embryogenesis is either lethal or can lead to the development of  
311 mitochondrial disorders (Chinnery and Hudson, 2013). Deleterious mtDNA mutations are a  
312 common cause of mitochondrial diseases and during development selection against mutant  
313 mtDNA has been described to occur through at least through two mechanisms, the bottleneck  
314 effect and intra-cellular purifying selection. The bottleneck effect is associated specifically with the  
315 unequal segregation of mtDNAs during primordial germ cell specification, for example as seen in  
316 the human embryo (Floros et al., 2018). In contrast to this, purifying selection, as the name implies,  
317 allows for selection against deleterious mtDNAs and has been proposed to take place both during  
318 development and post-natal life (Burr et al., 2018). Importantly, purifying selection has been found  
319 to occur not only at the organelle level, but also at the cellular level (Rajasimha et al., 2008). Our

320 findings indicate that purifying selection can occur not only at the intra-cellular level but also inter-  
321 cellularly (cell non-autonomously). We show that epiblast cells are able to sense their relative  
322 mitochondrial activity and that those cells with mtDNA mutations, lower or aberrant mitochondrial  
323 function are eliminated. By selecting those cells with the most optimised mitochondrial  
324 performance, cell competition would not only prevent cells with mitochondrial defects from  
325 contributing to the germline or future embryo, but also ensure optimization of the bioenergetic  
326 performance of the epiblast, contributing to the synchronization of growth during early  
327 development.

328 Cell competition has been studied in a variety of organisms, from *Drosophila* to mammals, and it  
329 is likely that multiple different mechanisms fall under its broad umbrella (reviewed in (Bowling et  
330 al., 2019; Diaz-Diaz and Torres, 2019; Madan et al., 2018). In spite of this, there is considerable  
331 interest in understanding if there could be any common feature in at least some of the contexts  
332 where cell competition has been described. The first demonstration of cell competition in  
333 *Drosophila* was made by inducing clones carrying mutations in the ribosomal gene *Minute* (Morata  
334 and Ripoll, 1975) and this has become one of the primary models to study this process. Our finding  
335 that that during normal early mouse development cell competition eliminates cells carrying  
336 mutations in *mt-Rnr1* and *mt-Rnr2*, demonstrates that in the physiological context mutations in  
337 ribosomal genes also trigger cell competition. Furthermore, our observation that mis-patterned  
338 and karyotypically abnormal cells show impaired mitochondrial activity indicates that during early  
339 mouse development different types of defects impair mitochondrial function and trigger cell  
340 competition. Interestingly, mtDNA genes are amongst the top mis-regulated factors identified  
341 during cell competition in the mouse skin (Ellis et al., 2019). In the *Drosophila* wing disc oxidative  
342 stress, a general consequence of dysfunctional mitochondria, underlies the out-competition of  
343 *Minute* and *Mah-jong* mutant cells (Kucinski et al., 2017). Similarly, in Madin-Darby Canine Kidney  
344 (MDCK) cells, a loss of  $\Delta\psi_m$  occurs during the out-competition of RasV12 mutant cells and is key  
345 for their extrusion (Kon et al., 2017). These observations raise that possibility that differences in  
346 mitochondrial activity may be a key determinant of competitive cell fitness in a wide range of  
347 systems. Unravelling what mitochondrial features can lead to cellular differences that can be read  
348 between cells during cell competition will be key not only for understanding this process, but also  
349 to open up the possibility for future therapeutic avenues in the diagnosis or prevention of  
350 mitochondrial diseases.

## 351 **Acknowledgments**

352 We would like to thank Stephen Rothery for guidance and advice with confocal microscopy.  
353 Gratitude also goes to James Elliot and Bhavik Patel for performing cell sorts. Research in Tristan  
354 Rodriguez lab was supported by the MRC project grant (MR/N009371/1) and by the British Heart

355 Foundation centre for research excellence. Ana Lima was funded by a BHF centre of excellence  
356 PhD studentship. Shankar Srinivas was funded through Wellcome awards 103788/Z/14/Z and  
357 108438/Z/15/Z.

## 358 **Author Contributions**

359 A.L. performed most of the experimental wet lab work. J.B. and A.L. derived heteroplasmic mESC  
360 lines. J.B. performed heteroplasmy measurements in heteroplasmic mESCs. B.P. generated  
361 *Mfn2<sup>-/-</sup>* and *Drp1<sup>-/-</sup>* mESCs and J.M.S did characterisation of mitochondria shape and pluripotency  
362 status. D.H. performed embryo dissections, treatments and cell dissociation prior to scRNA-seq  
363 experiments. G.L. did the bioinformatic analysis of scRNA-seq data. E.M., N.J. and A.G.  
364 participated in the analysis of mitochondrial DNA heteroplasmy. A.D.G. performed the  
365 metabolomic studies using Metabolon platform and participated in embryo dissections and  
366 immunohistochemistry stainings for validation of results obtained by scRNA-seq. M.D, and M.K.  
367 performed the bioinformatic analysis of bulk RNA-seq experiments. N.J., S.S. and D.C.  
368 participated in the design of experimental work and analysis of results. A.L., G.L., A.S and T.R.  
369 interpreted results and wrote the paper. T.R. and A.S. directed and designed the research.

## 370 **Declaration of Interests**

371 The authors declare no competing interests.

## 372 **Figure titles and legends**

### 373 **Figure 1. Cells eliminated during early mouse embryogenesis have a distinct** 374 **transcriptional profile.**

375 (A) Experimental design. The number of cells in the two conditions (DMSO-treated and CI-treated)  
376 refers to the number of cells that passed the quality control.

377 (B) Identification of the clusters according to known gene markers from the different embryonic  
378 regions. Three clusters (clusters 1, 3 and 4) show marker genes of the epiblast (Epi), while the  
379 remaining clusters correspond to the extra-embryonic lineages visceral endoderm (VE; cluster 5)  
380 and extraembryonic ectoderm (ExE; cluster 2). The epiblast clusters are named “Winner”,  
381 “Intermediate” and “Loser” on the basis of the relative fraction of cells from CI-treated embryos  
382 they include (see panel E).

383 (C-D) UMAP visualization of the single-cell RNA-seq data, with cells coloured according to cluster  
384 (C) or condition (D). A region made up exclusively by cells from CI-treated embryos emerges.

385 (E) Ratio between the fraction of cells from DMSO-treated and CI-treated embryos in the three  
386 epiblast clusters. While the “winner” epiblast cluster shows an enrichment of cells from DMSO-  
387 treated embryos, the “intermediate” and the “loser” epiblast clusters are strongly enriched for cells  
388 from CI-treated embryos.

389 See also Figure S1

### 390 **Figure 2. A cell competition transcriptional signature is identified in cells eliminated during** 391 **mouse embryonic development**

392 (A) Diffusion map of epiblast cells (only from CI-treated embryos), coloured by cluster.

393 (B-C) IPA run on the list of genes differentially expressed along the diffusion trajectory (see Figure  
394 S2D) generated lists of top 5 molecular and cellular functions (B) and upstream regulators (C)  
395 found to be differentially activated in epiblast cells along the diffusion trajectory from winner  
396 (cluster 1) to loser status (cluster 4).

397 (D) Diffusion map of epiblast cells (only from CI-treated embryos) colored by diffusion pseudotime  
398 coordinate (dpt). The winner and the loser clusters are found at the two extremities of the  
399 trajectory, hence the dpt can be interpreted as a “losing score”.

400 (E) Losing score of the cells in the three epiblast clusters in CI-treated (left) or DMSO-treated  
401 (right) embryos. The losing score of the cells from DMSO-treated embryos was obtained by  
402 projecting them on the diffusion map shown in panel D (see Methods).

403 (F) Expression levels of genes (in rows) that are markers for naïve pluripotency (*Klf4* and *Klf5*),  
404 primed pluripotency (*Fgf5* and *Tdgf1*), mesoderm (*Mesp1* and *T*), neuroectoderm (*Neurod1* and  
405 *Sox1*) and endoderm (*Sox17*). Cells (in columns) are sorted by their losing scores. The genes  
406 marked with a \* are differentially expressed along the trajectory.

407 (G) Scatter plots of the expression levels of different marker genes in cells from the loser epiblast  
408 cells (cluster 4), suggesting that loser cells are mis-patterned.

409 See also Figure S2.

410 **Figure 3. Cells eliminated during early mouse embryogenesis have mitochondrial defects.**

411 (A) Top canonical pathways, identified by IPA, mis-regulated in loser cells in comparison to normal  
412 epiblast cells. The numbers at the end of each bar refer to total amount of genes involved in that  
413 pathway. The percentage refers to the number of genes found mis-regulated relative to the  
414 number total genes within each pathway. Statistical significance calculated with Fisher's exact test  
415 ( $p < 0.05$ ): Mitochondrial Dysfunction,  $-\log_{10}(p\text{-value}) = 21.1$ ; Oxidative Phosphorylation,  $-\log_{10}(p\text{-value}) = 18.6$ ; EIF2 signalling,  $-\log_{10}(p\text{-value}) = 11.9$ .

417 (B) Detail of changes in oxidative phosphorylation pathway identified in (A). Circular and oval  
418 shapes represent each of the ETC complexes (complexes I to V). Diamond shapes represent  
419 subunits of each ETC complex. Genes that are differentially expressed between loser and winner  
420 epiblast cells are colored in shades of red, with darker shades corresponding to lower values of  
421 FDR, which ranges from  $1.25E-51$  (for *Atp5b*) to  $5.42E-03$  (for *Ndufa11*). Grey color denotes  
422 genes that were not significant ( $FDR > 0.01$ ). White color denotes genes from the Knowledge Base  
423 that were not tested (e.g., because they were not detected in our dataset).

424 (C) Expression levels of some mitochondrial genes as a function of cells' losing score. *mt-Atp6*,  
425 mitochondrial DNA encoded ATP synthase membrane subunit 6; *mt-Nd3*, mitochondrial DNA  
426 encoded NADH dehydrogenase subunit 3; *Opa1*, optic atrophy 1; *Samm50*, sorting and assembly  
427 machinery component 50 homolog.

428 (D) Experimental design adopted to assess mitochondria function (OPA1 expression, by  
429 immunofluorescence or  $\Delta\psi_m$ , given by TMRM fluorescence) in epiblast cells from embryos where  
430 cell death was allowed (DMSO-treated) or inhibited (CI-treated). \* Micrograph of isolated epiblast  
431 (arrow) after embryo microdissection.

432 (E) Representative immunohistochemistry of OPA1 in E6.5 embryo where cell death was inhibited  
433 (CI-treated), quantified in (F). Loser cells are identified by low mTOR activation (low p-rpS6,  
434 arrowheads). Scale bar = 20  $\mu\text{m}$ .

435 (F) Quantification of OPA1 fluorescence in normal epiblast cells and loser cells. N=6 embryos with  
436 a minimum of 8 cells analysed per condition. Statistical analysis performed by Mann-Whitney test.

437 (G) Representative histogram of flow cytometry analysis of TMRM probe, indicative of  $\Delta\psi_m$ , in  
438 epiblast cells from embryos where cell death was allowed (DMSO-treated) or inhibited (CI-  
439 treated), quantified in (H).

440 (H) Frequency of epiblast cells with high or low TMRM fluorescence, according to range defined  
441 in (G) from embryos where cell competition was allowed (DMSO treated) or inhibited (CI-treated).

442 Statistical analysis done by two-way ANOVA, followed by Holm-Sidak's multiple comparisons test.

443 N=3 independent experiments. Data shown as mean  $\pm$  SEM.

444 See also Figure S3.

445 **Figure 4. Mitochondrial defects are a common feature of cells eliminated by cell**  
446 **competition.**

447 (A) Metabolic enrichment analysis of the TCA cycle and intermediate metabolites obtained using  
448 Metabolon platform for defective cells (*Bmpr1a*<sup>-/-</sup>, left bar and 4n, right bar), in comparison to wild-  
449 type cells during differentiation. Bars indicate compound levels relative to wild-type cells. Blue bars  
450 indicate compounds that are significantly depleted ( $p < 0.05$ ) and light blue bars indicate  
451 compounds that are almost significantly depleted ( $0.05 \leq p \leq 0.1$ ). Black bars indicate compounds  
452 that are depleted although not statistically significant in comparison to the levels found in wild-type  
453 cells. The enzymes on the pathway are represented as boxes and labelled by their canonical  
454 names.

455 (B-E) Metabolic flux analysis of wild-type and BMP-defective cells during differentiating conditions.  
456 Statistical analysis done with Mann-Whitney test. Analysis of oxygen consumption rate (OCR) as  
457 a measure of mitochondria function (mitochondria stress test) (B). Detail of metabolic parameters  
458 found changed from the analysis of the mitochondria stress test (C). Analysis of extracellular  
459 acidification rate (ECAR) as a measure of glycolytic function (glycolysis stress test) (D). Detail of  
460 metabolic parameters found changed from the analysis of the glycolysis stress test (E).

461 (F-G) Analysis of mitochondrial membrane potential ( $\Delta\psi_m$ ) in defective mESCs undergoing  
462 differentiation in separate or co-culture conditions. Representative histograms of TMRM  
463 fluorescence and quantification for wild-type and *Bmpr1a*<sup>-/-</sup> (F) and wild-type and 4n (G). Statistical  
464 analysis done by two-way ANOVA, followed by Holm-Sidak's multiple comparisons test.

465 (H) Representative micrographs of wild-type and *Bmpr1a*<sup>-/-</sup> cells co-cultured during differentiation  
466 and stained for marker of  $\Delta\psi_m$  (MitoTracker Red, top panel) or mitochondria mass (TOMM20,  
467 bottom panel). Nuclei are stained with Hoechst. Scale bar = 10  $\mu$ m.

468 (I-J) Western blot analysis of mitochondria mass markers TOMM20 (I) and mt-CO1 (J) for wild-  
469 type and *Bmpr1a*<sup>-/-</sup> cells during differentiation. Statistical analysis done with Mann-Whitney test.

470 (K) Analysis of mitochondrial membrane potential ( $\Delta\psi_m$ ) for wild-type, *Bmpr1a*<sup>-/-</sup> and *Bmpr1a*<sup>-/-</sup>  
471 ;*p53*<sup>-/-</sup> cells during differentiation. Representative histogram of TMRM fluorescence and  
472 quantification. Statistical analysis done by one-way ANOVA, followed by Holm-Sidak's multiple  
473 comparisons test.

474 Data shown as mean  $\pm$  SEM of a minimum of 3 independent experiments.

475 See also Figure S4.

476 **Figure 5. Manipulating mitochondria biology is sufficient to trigger cell competition.**



477 (A) Representative micrographs of wild-type, *Drp1*<sup>-/-</sup> and *Mfn2*<sup>-/-</sup> mESCs showing alterations in  
478 mitochondrial morphology in mutant cells. TOMM20 was used as mitochondrial marker and  
479 NANOG as a pluripotency marker. Nuclei are stained with Hoechst. Scale bar = 5  $\mu$ m.  
480 (B-C) Cell competition assays between wildtype mESCs and cells with altered morphology, *Drp1*<sup>-/-</sup>  
481 (B) and *Mfn2*<sup>-/-</sup> (C). The ratio of final/initial cell numbers in separate or co-culture is shown.  
482 Statistical analysis done with two-way ANOVA, followed by Holm-Sidak's multiple comparisons  
483 test.

484 **Figure 6. Intermediate and loser epiblast cells accumulate polymorphisms in mtDNA**  
485 **sequence.**

486 (A-G) mtDNA heteroplasmy, *H*, in epiblast cells from CI-treated embryos. Average heteroplasmy  
487 (considering all eleven polymorphisms that have a statistically significant dependence on the  
488 losing score; see Methods) as a function of cells' losing scores. The p-value was computed with  
489 a generalized linear model (A). mtDNA heteroplasmy for six positions within the *mt-Rnr1* gene (B-  
490 G). The heteroplasmy at all of these positions as well as the average heteroplasmy increase with  
491 the cells' losing scores in a statistically significant way (the adjusted p-value estimated via a  
492 generalized linear model is indicated at the top of each plot).

493 (H) The barplot indicates the fraction of epiblast cells in each of the cluster indicated on the x-axis  
494 (winner, intermediate, loser) that carry a mean heteroplasmy *H* (computed on the six positions  
495 within the *mt-Rnr1* indicated in the panels B-G) greater than 0.01. This shows that the level of  
496 mtDNA heteroplasmy in *mt-Rnr1* is strongly associated with the loser status of the cells, since  
497 ~55% and ~87% of cells in the intermediate and the loser clusters, respectively, have  
498 heteroplasmic sequences in this gene compared to only ~5% of cells in the winner cluster.

499 (I) Spearman's correlation coefficient between the mtDNA heteroplasmy at the six positions shown  
500 in panels (B-G).

501 See also Figure S5.

502 **Figure 7. Changes in mtDNA sequence can determine the competitive ability of a cell.**

503 (A) Derivation of mESCs from hybrid mouse strains, generated elsewhere by Burgstaller and  
504 colleagues. Neighbour-Joining Phylogenetic Analysis of mtDNA from wild and C57BL/6N mouse  
505 strains, that were used to generate hybrid mice (adapted from Burgstaller et al, 2014), illustrates  
506 the genetic distance of the mtDNA from wild mouse strains to the C57BL/6N lab mouse. The  
507 number of single nucleotide polymorphisms and amino acid changes (SNPs/ a.a. changes) from  
508 wild to lab mouse strain is shown. mESCs were derived from embryos of hybrid mice, containing  
509 the nuclear background of a C57BL/6N lab mouse and mtDNA from three possible wild-derived  
510 strains (BG, HB or ST).

511 (B-E) Cell competition assays between cells derived from the embryos of hybrid mice. The ratio  
512 of final/initial cell numbers in separate or co-culture is shown. Statistical analysis done with two-  
513 way ANOVA, followed by Holm-Sidak's multiple comparisons test.

514 (F) Representative micrographs of cleaved caspase-3 staining and quantification of the  
515 percentage of apoptotic events in winners HB(24%) and loser BG(95%) mESCs and cultured in  
516 separate or co-culture conditions. Statistical analysis done with two-way ANOVA, followed by  
517 Holm-Sidak's multiple comparisons test.

518 (G-H) Gene set enrichment analysis of differentially expressed genes from bulk RNA seq. in loser  
519 loser BG (95%) compared to winner HB (24%) mESCs cultured in separate (J) or co-culture  
520 conditions (K). Gene sets that show positive normalized enrichment scores (NES) are enriched in  
521 loser cells, while gene sets that show negative NES are depleted in loser cells.

522 (I) Summary of the main findings of the study. A range of cellular defects, such as aneuploidy,  
523 mis-patterning or mtDNA mutations cause alterations in mitochondria function, which affect the  
524 relative fitness of cells. The cells with suboptimal mitochondrial activity survive in a homogeneous  
525 population, but are eliminated by cell competition in the presence of fitter cells.

526 Data in panels (B-F) shown as mean  $\pm$  SEM of a minimum of 3 independent experiments.

527 See also Figure S6.

#### 528 **Figure S1. Quality controls of scRNA-seq**

529 (A) These boxplots show the log<sub>10</sub>-total number of reads (top left), the fraction of mapped reads  
530 (top central), the fraction of reads mapped to endogenous genes (top right), the fraction of reads  
531 mapped to mitochondrial genes (bottom left), the fraction of reads mapped to ERCC spike-ins  
532 (bottom central) and the number of genes with more than 10 reads per million (bottom right) for all  
533 cells (723) that passed the quality control.

534 (B) Number of good quality cells in each condition (rows) and batch (columns).

535 (C) Number of good quality cells per cluster (rows) and batch (columns).

536 (D) UMAP plot of the data with cells colored by batch. In each batch there is a balanced  
537 distribution of cells in the two conditions and across the five clusters.

#### 538 **Figure S2. Analysis on epiblast cells from DMSO and CI-treated embryos**

539 (A-B) Diffusion map analysis in all epiblast cells (from DMSO and CI-treated embryos): cells are  
540 coloured according to the condition (A) and to the cluster (B).

541 (C) The pseudo-time coordinate of the CI-treated epiblast cells obtained from the diffusion map  
542 including all epiblast cells correlates extremely well with the pseudo-time coordinate obtained in  
543 the diffusion map calculated only from CI-treated epiblast cells (Figure 2A).

544 (D) Heatmap showing the expression pattern of all genes differentially expressed along the  
545 trajectory from winning to losing cells in Figure 2D.

546 (E-F) Overlap of genes differentially expressed along the trajectory joining winning and losing  
547 epiblast cells in CI-treated embryos (Figure 2A and S2D) and genes targeted by p53. Pie charts  
548 show the percentage of genes up- or down-regulated in loser cells within the group of target genes  
549 that are activated (E) or repressed (F) by p53. There is an enrichment of activated/repressed  
550 targets among genes upregulated/downregulated in losing cells respectively (Fisher's test, p-  
551 value=1E-4). The list of p53 targets is taken from (Fischer, 2017).

552 **Figure S3. Cells eliminated during early mouse embryogenesis have activated stress**  
553 **responses.**

554 (A) Overlap of genes differentially expressed along the trajectory joining winning and losing  
555 epiblast cells in CI-treated embryos (Figure 2A and Figure S2F) and genes related to the unfolded  
556 protein response and integrated protein response pathways (UPR\_ISR, see Supplementary Table  
557 3). From the 32 genes related to the UPR & ISR pathways, 12 are down-regulated in loser cells,  
558 8 genes are up-regulated in loser cells, and 12 genes are not differentially expressed between  
559 loser and winner cells. There is a statistically significant enrichment of UPR&ISR genes among  
560 the up-regulated genes in loser cells (Fisher test, odds ratio=3.0, p-value=0.012). The intersection  
561 between UPR-ISR genes and the down regulated genes is not significant (Fisher test, odds  
562 ratio=1.2, p value=0.69).

563 (B-C) List of genes from UPR-ISR pathways that are statistically significantly upregulated (B) or  
564 downregulated (C) in loser cells.

565 (D) Scatterplots with the expression levels of genes involved in stress responses in epiblast cells  
566 from CI-treated embryos as a function of cells' losing score.

567 (E) Experimental design with the approach taken to validate the expression of the stress response  
568 marker DDIT3 in epiblast cells from DMSO or CI-treated embryos.

569 (F) Representative micrographs of DMSO (upper panel) or CI-treated embryos (100  $\mu$ M, lower  
570 panel) stained for DDIT3, quantified in (G). Nuclei are labelled with Hoechst. In control embryos  
571 (DMSO-treated), dying cells in the cavity show very high DDIT3 expression (arrow), while live cells  
572 in the epiblast of the CI-treated embryos show more modest levels of DDIT3 expression  
573 (arrowheads). Scale bar = 20  $\mu$ m.

574 (G) Quantification of the percentage of epiblast cells with nuclear DDIT3 expression. N=10 DMSO  
575 and N=9 CI-treated embryos. Data shown as mean  $\pm$  SEM.

576 *Ddit3* (*Chop*), DNA-damage inducible transcript 3; *Atf3*, activating transcription factor 3; *Atf4*,  
577 activating transcription factor 4; *Foxo3*, forkhead box O3; *Ppp1r115a* (*Gadd34*), Protein  
578 Phosphatase 1 Regulatory Subunit 15A, *Eif2ak3* (*Perk*), Eukaryotic Translation Initiation Factor 2  
579 Alpha Kinase 3; *Nfe2l2* (*Nrf2*), NFE2-related factor 2;. *Sesn2*, Sestrin 2; *Gdf15*, Growth  
580 Differentiation Factor 15; *Mthfd1l*, Methylene tetrahydrofolate Dehydrogenase (NADP+  
581 Dependent) 1 Like; *Hspe1*, Heat Shock Protein Family E (*Hsp10*) Member 1; *Cat*, Catalase;

582 *Hspd1*, Heat Shock Protein Family D (Hsp60) Member 1; *Sod2*, Superoxide Dismutase 2; *Hsph1*,  
583 Heat Shock Protein Family H (*Hsp110*) Member 1; *Lonp1*, Lon Peptidase 1, Mitochondrial; *Eif2a*,  
584 Eukaryotic Translation Initiation Factor 2A; *Mthfd2*, Methylene tetrahydrofolate Dehydrogenase  
585 (NADP<sup>+</sup> Dependent) 2, Methenyltetrahydrofolate Cyclohydrolase; *Hspa4*, Heat Shock Protein  
586 Family A (*Hsp70*) Member 4; *Cth*, Cystathionine Gamma-Lyase; *Nrf1*, Nuclear Factor 1.

587 **Figure S4. Mitochondrial function in Wild-type, *Bmpr1a*<sup>-/-</sup> and 4n mESCs**

588 (A-F), Metabolic analysis of wild-type and *Bmpr1a*<sup>-/-</sup> mESCs. OCR profile during the mitochondria  
589 stress test performed in pluripotency conditions (A). Metabolic parameters assessed during the  
590 mitochondria stress test performed in pluripotency conditions (B). ECAR profile during the  
591 glycolysis stress test performed in pluripotency conditions (C). Metabolic parameters assessed  
592 during the glycolysis stress test performed in pluripotency conditions (D). Metabolic parameters  
593 from the mitochondria stress test found to be similar between wild-type and *Bmpr1a*<sup>-/-</sup> mESCs  
594 during differentiation (E). Metabolic parameters from the glycolysis stress test found to be similar  
595 between wild-type and *Bmpr1a*<sup>-/-</sup> mESCs during differentiation (F).

596 (G-H) Analysis of mitochondrial membrane potential ( $\Delta\psi_m$ ) in defective mESCs maintained in  
597 pluripotency conditions, in separate or co-culture. Representative histograms of TMRM  
598 fluorescence and quantification for wild-type and *Bmpr1a*<sup>-/-</sup> (G) and wild-type and 4n (H). Statistical  
599 analysis done by two-way ANOVA, followed by Holm-Sidak's multiple comparisons test.

600 (I) Analysis of mitochondrial ROS in wild-type and *Bmpr1a*<sup>-/-</sup> mESCs undergoing differentiation in  
601 separate or co-culture: representative histograms of mitoSOX Red fluorescence and quantification  
602 of the percentage of mitoSOX positive cells.

603 Data obtained with a minimum of 3 independent experiments. Error bars represent SEM.

604 **Figure S5. Analysis of SNPs in mtDNA in epiblast cells.**

605 (A-E) mtDNA heteroplasmy, *H*, in epiblast cells from CI-treated embryos for five positions within  
606 the *mt-Rnr2* gene. All of these positions have an heteroplasmy that increases with the cells' losing  
607 scores in a statistically significant way (the adjusted p-value estimated via a generalized linear  
608 model is indicated at the top of each plot).

609 (F-K) The variation in the heteroplasmy across the CI-treated cells is not due to a batch effect for  
610 the 6 significant positions within the *mt-Rnr1* gene.

611 (L) Spearman's correlation between the mtDNA heteroplasmy at all the statistically significant  
612 positions (six within the gene *mt-Rnr1* and five within the gene *mt-Rnr2*).

613 **Figure S6. Changes in mtDNA sequence are enough to trigger cell competition.**

614 (A) Illustration of the process of derivation of the mESCs lines from mice that are hybrid between  
615 the wild-caught strains (BG, HB or ST) and the lab mouse (C57BL/6N). These hybrid mice were  
616 generated elsewhere (Burgstaller et al, 2014) by ooplasmic transfer: the zygote of a C57BL/6N

617 mouse was injected with ooplasm from a wild-caught mouse (orange, HB pictured). Therefore,  
618 these hybrid mice contain the nuclear background of the C57BL/6N strain and the mtDNA of wild-  
619 caught strain and potentially C57BL/6N mtDNA (heteroplasmic mice strains). mESCs lines were  
620 derived from the hybrid mice and characterised.

621 (B-F) Characterisation of cell lines derived by flow cytometry in comparison to the wild-type cell  
622 line used in previous experiments (E14, 129/Ola background). Heteroplasmy analysis of the  
623 derived mESC lines from the hybrid mice, indicating the percentage of wild-derived mtDNA (B).  
624 Cell granularity (internal complexity) given as median fluorescence intensity of SSc-A laser (C).  
625 Cell size given as median fluorescence intensity of FSc-A laser (D). Analysis of the expression of  
626 mitochondrial markers: representative western blot and quantification of markers of mitochondrial  
627 mass (ATPB, mt-CO1 and TOMM20) and mitochondrial dynamics (DRP1, MFN1 and MFN2),  
628 relative to vinculin, in cells derived from hybrid mice (E). Representative histograms and  
629 quantification of median TMRM fluorescence, indicative of  $\Delta\psi_m$ , for the hybrid cell lines derived,  
630 in comparison to the wild-type cell line used in previous experiments (E14, 129/Ola  
631 background)(F). Statistical analysis done by one-way ANOVA, followed by Holm-Sidak's multiple  
632 comparisons test.

633 (G-I) Cell competition assays between hybrid cell lines. The ratio of final/initial cell numbers in  
634 separate or co-culture is shown. Statistical analysis done by two-way ANOVA, followed by Holm-  
635 Sidak's multiple comparisons test.

636 (J) Experimental design for RNA-Seq and GSEA. The isolation of RNA from winner HB(24%) and  
637 loser BG(95%) cells was performed after three days in separate or co-culture conditions, once  
638 cells have been subjected to FACS to isolate the two populations from mixed cultures.

639 Data obtained with a minimum of 3 independent experiments. Error bars represent SEM.

#### 640 **Figure S7. Common features of scRNA-seq and bulk RNA-seq datasets.**

641 (A) Terms significantly enriched among genes downregulated in BG(95%) (loser) ESCs *in vitro*  
642 when co-cultured with HB(24%) cells. The loss of mitochondrial activity emerges as a common  
643 feature between loser cells *in vivo* and *in vitro*. The gene enrichment analysis was performed  
644 using g-profiler tool (see Methods).

645 (B) Intersection between differentially expressed genes along the trajectory from winning to losing  
646 epiblast cells ("in\_vivo\_scRNA-seq"; Figure 2A and S2D) and genes differentially expressed  
647 between co-cultured HB(24%) (winner) and BG(95%) (loser) ESCs ("in\_vitro\_bulk\_RNA-seq").  
648 "Up" and "Down" here refer to genes up- or down-regulated in loser cells. Fisher test for the  
649 intersection between down-regulated genes from scRNA-seq (*in vivo*) and down-regulated genes  
650 from bulk RNA-seq (*in vitro*): p-value, 1.71E-12; odds ratio 1.80. Fisher test for the intersection  
651 between down-regulated genes from scRNA-seq (*in vivo*) and up-regulated genes from bulk RNA-  
652 seq (*in vitro*): p-value, 5.20E-3; odds ratio 0.67. Fisher test for the intersection between up-

653 regulated genes from scRNA-seq (*in vivo*) and down-regulated genes from bulk RNA-seq (*in vitro*):  
654 Fisher test p-value, 4.87E-3; odds ratio 0.80. The intersection between up-regulated genes from  
655 sc-RNA-seq (*in vivo*) and up-regulated genes from bulk RNA-Seq (*in vitro*) is not statistically  
656 significant: Fisher test p-value: 0.30, odds ratio 1.14.

657 (C) Intersection between the significantly enriched terms in genes upregulated or downregulated  
658 in loser cells in the epiblast of CI-treated embryos ("*in\_vivo\_scRNA-Seq*") or in our *in vitro* model  
659 of competition between co-cultured HB(24%) (winner) and BG(95%) (loser) ESCs  
660 ("*in\_vitro\_bulk\_RNA-seq*"). All the terms enriched among downregulated genes *in vitro* are also  
661 enriched *in vivo*.

## 662 **List of Tables.**

663 **Supplementary Table 1.** List of genes down-regulated along the winner-to-loser trajectory in the  
664 embryo.

665 **Supplementary Table 2.** List of genes up-regulated along the winner-to-loser trajectory in the  
666 embryo.

667 **Supplementary Table 3.** Genes related to the unfolded protein response and integrated protein  
668 response pathways (UPR\_ISR) that were analysed in the genes differentially expressed along the  
669 winner-to-loser trajectory.

670 **Supplementary Table 4.** List of background genes for the winner-to-loser trajectory in the  
671 embryo.

672 **Supplementary Table 5.** List of genes down-regulated in BG(95%) cells when co-cultured with  
673 HB(24%) cells.

674 **Supplementary Table 6.** List of genes up-regulated in BG(95%) cells when co-cultured with  
675 HB(24%) cells.

676 **Supplementary Table 7.** List of background genes used for the analysis of genes differentially  
677 expressed between co-cultured BG(95%) and HB(24%) cells .

## 678 **STAR Methods**

### 679 **KEY RESOURCES TABLE**

680 Presented in a separate file

### 681 **LEAD CONTACT AND MATERIALS AVAILABILITY**

682 Tristan Rodriguez: [tristan.rodriguez@imperial.ac.uk](mailto:tristan.rodriguez@imperial.ac.uk) and Antonio Scialdone

683 [antonio.scialdone@helmholtz-muenchen.de](mailto:antonio.scialdone@helmholtz-muenchen.de)

### 684 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

#### 685 **Cell lines and cell culture routine**

686 E14, kindly provided by Prof A. Smith, from Cambridge University, were used as wild-type control  
687 cells tdTomato-labelled or unlabelled. GFP-labelled or unlabelled cells defective for BMP  
688 signalling (*Bmpr1a*<sup>-/-</sup>), tetraploid cells (4n) and *Bmpr1a*<sup>-/-</sup> null for p53 (*Bmpr1a*<sup>-/-</sup>;*p53*<sup>-/-</sup>) are described  
689 elsewhere (Bowling et al., 2018; Sancho et al., 2013). Cells null for Dynamin-related protein 1  
690 (*Drp1*<sup>-/-</sup>) or Mitofusin 2 (*Mfn2*<sup>-/-</sup>) were generated by CRISPR mutagenesis. Cells with different  
691 mitochondrial DNA (mtDNA) content in the same nuclear background were derived from embryos  
692 of hybrid mice, generated elsewhere (Burgstaller et al., 2014).

693 Cells were maintained pluripotent and cultured at 37°C in 5% CO<sub>2</sub> in 25 cm<sup>2</sup> flasks (Nunc) coated  
694 with 0.1% gelatin (Sigma) in DPBS. Growth media (ES media) consisted of GMEM supplemented  
695 with 10% FCS, 1mM sodium pyruvate, 2 mM L-glutamine, 1X minimum essential media non-  
696 essential amino-acids, 0.1 mM β-mercaptoethanol (all from Gibco) and 0.1% leukemia inhibitory  
697 factor (LIF, produced and tested in the lab). Cells derived from hybrid mice (C57BL/6N nuclear  
698 background) were maintained on 0.2% LIF. The growth media was changed daily, and cells were  
699 split every 3 days.

#### 700 **CRISPR mutagenesis**

701 *Drp1* and *Mfn2* knockout ESCs were generated by CRISPR-Cas9 mediated deletion of *Drp1* exon  
702 2 and *Mfn2* exon 3 respectively. sgRNA guides flanking *Drp1* exon 2 or *Mfn2* exon 3 were cloned  
703 into the PX459 vector (Addgene)(Ran et al., 2013): *Drp1* exon 2 upstream sgRNA:  
704 5' TGGAACGGTCACAGCTGCAC 3'; *Drp1* exon 2 downstream sgRNA:  
705 5' TGGTCGCTGAGTTTGAGGCC 3'; *Mfn2* upstream sgRNA: 5' GTGGTATGACCAATCCCAGA  
706 3'; *Mfn2* downstream sgRNA: 5' GGCCGGCCACTCTGCACCTT 3'. E14 ESCs were co-  
707 transfected with 1ug of each sgRNA expression using Lipofectamine 2000 (Invitrogen) according  
708 to manufacturer's instructions. As control E14 ESCs were transfected in parallel with equal amount  
709 of empty PX459 plasmid. Following 6 days of Puromycin selection, single colonies were picked  
710 from both *Drp1* sgRNA and empty vector transfected ESCs and screened for mutations. *Drp1*  
711 exon 2 deletion was confirmed by PCR genotyping using the following primers: *Drp1*\_genot F: 5'  
712 GGATACCCCAAGATTTCTGGA 3'; *Drp1*\_genot R: 5' AGTCAGGTAATCGGGAGGAAA 3',

713 followed by Sanger Sequencing. Mfn2 exon 3 deletion was confirmed by PCR genotyping using  
714 the following primers: Mfn2\_genot F: 5' CAGCCCAGACATTGTTGCTTA 3'; Mfn2\_genot R: 5'  
715 AGCTGCCTCTCAGGAAATGAG 3', followed by Sanger Sequencing.

## 716 **Derivation of mESCs from hybrid mouse strains**

717 The derivation of new mESC lines was adapted from (Czechanski et al., 2014). Heteroplasmic  
718 mESCs were derived from embryos of hybrid mouse strains BG, HB and ST. These contain the  
719 mtDNA of C57BL/6N (B16) lab mouse and mtDNA variants from wild-caught mice (Burgstaller et  
720 al., 2014).

721 Embryos were isolated at E2.5 (morula stage) and cultured in 4-well plates (Nunc, Thermo  
722 Scientific) containing KSOM media (Millipore) plus two inhibitors (KSOM+2i): 1  $\mu$ M MEK inhibitor  
723 PDO325901 (Sigma-Aldrich) and 3  $\mu$ M GSK-3 inhibitor CHIR9902 (Cayman Chemicals) for 2 days  
724 at 37°C in 5% CO<sub>2</sub> incubator. To reduce evaporation, the area surrounding the wells was filled  
725 with DPBS. Embryos were further cultured in a fresh 4-well plates containing, N2B27+2i+LIF  
726 media: N2B27 media supplemented with 1  $\mu$ M MEK inhibitor PDO325901 and 3  $\mu$ M GSK-3  
727 inhibitor and 0.1% LIF for up to 3 days until reaching the blastocyst stage. Each embryo was then  
728 transferred to a well of a 96-well plate coated with 0.1% gelatin in DPBS and containing 150  $\mu$ L of  
729 N2B27+2i+LIF media per well. In these conditions, the embryos should attach to the wells allowing  
730 the epiblast to form an outgrowth. This plate was then incubated at 37°C in 5% CO<sub>2</sub> incubator for  
731 3 to 7 days until ES-like colonies start to develop from the epiblast outgrowth. Cells were passaged  
732 by dissociation with Accutase (Sigma) and seeded in gradual increasing surface area of growth  
733 (48-well, 24-well, 12-well plate, T12.5 and T25 flask), until new cell lines were established. At this  
734 stage cells were weaned from N2B27+2i+LIF media and then routinely cultured in ES media.

## 735 **Animals**

736 Mice were maintained and treated in accordance with the Home Office's Animals (Scientific  
737 Procedures) Act 1986. All mice were housed on a 10 hr-14 hr light-dark cycle with access to water  
738 and food *ad libitum*. Mattings were generally set up in the afternoon. Noon of the day of finding a  
739 vaginal plug was designated embryonic day 0.5 (E0.5). Embryo dissection was performed at  
740 appropriate timepoints in M2 media (Sigma), using Dumont No.5 forceps (11251-10, FST). No  
741 distinction was made between male and female embryos during the analysis.

## 742 **METHOD DETAILS**

### 743 **Embryo experiments**

744 Early mouse embryos were isolated at E5.5 (from pregnant CD1 females, purchased from Charles  
745 River, UK). Following dissection from the decidua, embryos were cultured overnight in N2B27  
746 "poor" media (same formulation as N2B27 media but supplemented with 0.5xN2 supplement and  
747 0.5xN2 supplement) with pan-caspase inhibitors (100  $\mu$ M, Z-VAD-FMK, FMK001, R&D Systems,



748 USA) or equal volume of vehicle (DMSO) as control. On the next morning, embryos were  
749 processed for single cell RNA-Seq (scRNA-seq) or functional validation ( $\Delta\psi$ m analysis and  
750 immunohistochemistry for markers of loser cells).

751 For the scRNA-seq and  $\Delta\psi$ m analysis embryos were dissociated into single-cells. Briefly, up to 12  
752 embryos were dissociated in 600  $\mu$ L Accutase (A6964, Sigma, UK) during 12 min at 37°C,  
753 tapping the tube every two minutes. Accutase was then neutralised with equal volume of FCS,  
754 cells spun down and stained with TMRM, for  $\Delta\psi$ m analysis, or directly re-suspended in 300  $\mu$ L  
755 DPBS with 1% FCS, for single cell sorting and RNA-seq. Sytox blue (1:1000, S34857,  
756 ThermoFisher Scientific, UK), was used as viability staining.

### 757 **Cell competition assays**

758 Cell competition assays between wild-type and *Bmpr1a*<sup>-/-</sup>, 4n or *Drp1*<sup>-/-</sup> cells were performed in  
759 differentiating conditions. Cells were seeded onto fibronectin-coated plates (1:100, Merck) in  
760 DPBS during 1h at 37°C and grown in N2B27 media - to promote the differentiation of mESCs into  
761 a stage resembling the post-implantation epiblast, as cell competition was previously shown to  
762 occur in these conditions (Sancho et al., 2013). N2B27 media consisted of 1:1 Dulbecco's modified  
763 eagle medium nutrient mixture (DMEM/F12) and Neurobasal supplemented with N2 (1x) and B27  
764 (1x) supplements, 2 mM L-glutamine and 0.1 mM  $\beta$ -mercaptoethanol - all from Gibco. Cell  
765 competition assays between wild-type and *Mfn2*<sup>-/-</sup> and between mESCs with different mtDNA  
766 content were performed in pluripotency maintenance conditions (ES media).

767 Cells were seeded either separately or mixed for co-cultures at a 50:50 ratio, onto 12 well plates,  
768 at a density of 8E04 cells per well, except for assays between wild-type and *Mfn2*<sup>-/-</sup> mESCs, where  
769 3.2E05 cells were seeded per well. The growth of cells was followed daily and compared between  
770 separate or co-culture, to control for cell intrinsic growth differences, until the fourth day of culture.  
771 Viable cells were counted daily using Vi-CELL XR Analyser (Beckman Coulter, USA), and  
772 proportions of each cell type in co-cultures were determined using LSR II Flow Cytometer (BD  
773 Bioscience), based on the fluorescent tag of the ubiquitously expressed GFP or TdTomato in one  
774 of the cell populations.

### 775 **Metabolomic Analysis**

776 The metabolic profile was obtained using the Metabolon Platform (Metabolon, Inc). Each sample  
777 consisted of 5 biological replicates. For each replicate, 1E07 cells were spun down and snap  
778 frozen in liquid nitrogen. Pellets from 5 independent experiments for each condition were analysed  
779 by Metabolon Inc by a combination of Ultrahigh Performance Liquid Chromatography-Tandem  
780 Mass Spectroscopy (UPLC- MS/MS) and Gas Chromatography-Mass Spectroscopy (GC-MS).  
781 Compounds were identified by comparison to library entries of purified standards based on the  
782 retention time/index (RI), mass to charge ratio (*m/z*), and chromatographic data (including MS/MS

783 spectral data) on all molecules present in the library. Samples were normalized to protein content  
784 measured by Bradford assay. Statistical analysis was done using Welch's two-sample t-test and  
785 statistical significance defined as  $p \leq 0.05$ .

### 786 **Analysis of mitochondrial membrane potential ( $\Delta\psi_m$ )**

787 Quantitative analysis of  $\Delta\psi_m$  was performed by flow cytometry. Cells were grown in pluripotency  
788 or differentiating conditions, as described above. Cells were dissociated and pelleted to obtain  
789 2E05 cells per sample for the staining procedure.

790 For TMRM staining in single cells from early mouse epiblasts, embryos were dissected at E5.5  
791 and cultured overnight in the presence or absence of caspase inhibitors. On the following morning,  
792 to avoid misleading readings, epiblasts were isolated initially by an enzymatic treatment with of  
793 2.5% pancreatin, 0.5% trypsin and 0.5% polyvinylpyrrolidone (PVP40) - all from Sigma-Aldrich- to  
794 remove the visceral endoderm (VE). Embryos were treated during 8 min at 4°C, followed by 2 min  
795 at RT. The VE was then peeled with the forceps and the extraembryonic ectoderm removed to  
796 isolate the epiblasts. Up to 16 epiblasts were pooled per 600 $\mu$ L of Accutase (Sigma-Aldrich) for  
797 dissociation into single cells prior to staining. Reaction was stopped with equal volume of FCS and  
798 cells subjected to TMRM staining.

799 Cells were loaded with 10 nM of the Nernstian probe tetramethylrhodamin methyl ester perchlorate  
800 (TMRM, Sigma), prepared in N2B27 media. After incubating for 15 min at 37°C, cells were pelleted  
801 again and re-suspended in flow cytometry (FC) buffer (3% FCS in DPBS). Sytox blue (1:1000,  
802 Invitrogen, UK) was used as viability staining. Stained cell suspensions were analysed in BD LSRII  
803 flow cytometer operated through FACSDiva software (Becton Dickinson Biosciences, UK). For  
804 TMRM fluorescence detection the yellow laser was adjusted for excitation at  $\lambda=562$  nm, capturing  
805 the emission light at  $\lambda=585$  nm for TMRM (Floryk and Houštek, 1999; Scaduto and Grotyohann,  
806 1999). In the case of GFP-labelled cell lines, for GFP fluorescence detection the blue laser was  
807 adjusted for excitation at  $\lambda=488$  nm, capturing the emission light at  $\lambda=525$  nm. Results were  
808 analysed in FlowJo vX10.0.7r2.

809 Qualitative analysis of  $\Delta\psi_m$  was performed by confocal microscopy. Wild-type and *Bmpr1a*<sup>-/-</sup> cells  
810 were grown in fibronectin-coated glass coverslips. At the third day of differentiation, cells were  
811 loaded with 200 nM MitoTracker Red probe (Life Technologies), prepared in N2B27 media, for 15  
812 min at 37°C. Cells were then washed with DPBS and fixed with 3.7% formaldehyde for subsequent  
813 immunocytochemical staining of total mitochondria mass, with TOMM20 antibody.

### 814 **Immunofluorescence**

815 Cells were washed with DPBS and fixed with 3.7% formaldehyde (Sigma, UK) in N2B27, for 15  
816 min at 37°C. Permeabilization of the cell membranes was done with 0.4% Triton X-100 in DPBS  
817 (DPBS-Tx), at RT with agitation. Blocking step with 5% BSA in DPBS-Tx 0.1% was performed for

818 30 min, at RT with agitation. Mitochondria were labelled with TOMM20 antibody (1:100, Santa  
819 Cruz Biotechnologies). Dead cells were labelled with cleaved caspase-3 antibody (1:400, CST)  
820 and NANOG antibody was used to mark pluripotent cells (1:100, eBioscience). Secondary  
821 antibodies were Alexa Fluor (1:600, Invitrogen). Primary antibody incubation was performed  
822 overnight at 4°C and secondary antibody incubation during 45 min, together with Hoechst to stain  
823 nuclei (1:1000, ThermoScientific), at RT and protected from light. In both cases antibodies were  
824 diluted in blocking solution. Three 10 min washes with DPBS-Tx 0.1% were performed between  
825 each critical step and before mounting with Vectashield medium (Vector Laboratories).

826 Samples were imaged with a Zeiss LSM780 confocal microscope (Zeiss, UK) and processed with  
827 Fiji software (Schindelin et al., 2012). Mitochondria stainings were imaged with a 63x/1.4 Oil  
828 objective. For samples stained with TOMM20 antibody and MitoTracker Red, Z-stacks were  
829 acquired and processed for deconvolution using Huygens software (Scientific Volume Imaging,  
830 <https://svi.nl/>). Samples stained with cleaved caspase-3 were imaged with 20x/0.8 magnification  
831 objective. Imaging and deconvolution analysis were performed with the support and advice from  
832 Mr. Stephen Rothery from the Facility for Imaging by Light Microscopy (FILM) at Imperial College  
833 London.

834 Embryo immunofluorescent staining for p-rpS6, OPA1 and DDIT3 (CHOP) markers was  
835 performed as follows. Cultured embryos were fixed in 4% PFA in DPBS containing 0.01% Triton  
836 and 0.1% Tween 20 during 20 min at RT. Permeabilization of the membranes was done during  
837 10 min in DPBS with 0.5% Triton. Embryos were blocked in 5% BSA in DPBS with 0.25% Triton  
838 during 45 min. Incubation with primary antibodies - CHOP (1:500, CST), OPA1 (1:100, BD  
839 Biosciences) and p-rpS6 (CST, UK) - was done overnight at 4°C in 2.5% BSA in DPBS with  
840 0.125% Triton. On the following morning, hybridisation with secondary antibodies Alexa Fluor 568  
841 and Alexa Fluor 488 (diluted 1:600 in DPBS with 2.5% BSA and 0.125% Triton) was done next  
842 during 1h at RT. Hoechst was also added to this mixture to stain nuclei (1:1000). Three 10 min  
843 washes with filtered DPBS-Tx 0.1% were performed between each critical step. All steps were  
844 done with gentle agitation.

845 Embryos were imaged in embryo dishes (Nunc) in a drop of Vectashield using Zeiss LSM780  
846 confocal microscope at 40x magnification.

#### 847 **Western Blotting**

848 Cells were washed in DPBS and lysed with Laemmli lysis buffer (0.05 M Tris- HCl at pH 6.8, 1%  
849 SDS, 10% glycerol, 0.1%  $\beta$ -mercaptoethanol in distilled water). Total protein quantification was  
850 done using BCA assay (Thermo Scientific, UK) and samples (15 $\mu$ g of protein per lane) were  
851 loaded into 12% Bis-Tris protein gels (BioRad). Resolved proteins were transferred into  
852 nitrocellulose membranes (GE Healthcare). The following primary antibodies were incubated

853 overnight at 4°C: rabbit anti-TOMM20 (1:1000, CST-42406), rabbit anti- $\alpha$ -Tubulin (1:1000, CST-  
854 2144), mouse anti-mt-CO1 (1:2000, ab14705), rabbit anti-DRP1 (1:1000, CST- 8570), mouse anti-  
855 MFN1 (ab57602), mouse anti-MFN2 (ab56889) and mouse anti-Vinculin (1:1000, Sigma V9131).  
856 On the following morning, HRP-conjugated secondary antibodies (Santa Cruz) were incubated for  
857 1h at RT. Membranes were developed with ECL reagents (Promega) and mounted in cassette  
858 for time-time-controlled exposure to film (GE Healthcare).

### 859 **Bulk RNA-Seq and Single cell RNA-Seq**

860 For bulk RNA Seq in the competitive scenario between cells with different mtDNA, HB(24%) and  
861 BG(95%) mESCs were grown separately or in co-culture. On the third day of culture cells were  
862 dissociated and subjected to fluorescence activated cell sorting (FACS) to separate the cell  
863 populations in co-culture. To control for eventual transcriptional changes due to the FACS process,  
864 a mixture of the two separate populations was subjected to the same procedure as the co-cultured  
865 samples. Total RNA isolation was then carried out using RNA extraction Kit (RNeasy Mini Kit,  
866 Qiagen). PolyA selection/enrichment was the method adopted for library preparation, using the  
867 NEB Ultra II RNA Prep Kit. Single end 50bp libraries were sequenced on Illumina Hiseq 2500.  
868 Raw basecall files were converted to fastq files using Illumina's bcl2fastq (version 2.1.7). Reads  
869 were aligned to mouse genome (mm9) using Tophat2 version 2.0.11 (Kim et al., 2013) with default  
870 parameters. Mapped reads that fell on genes were counted using featureCounts from Rsubread  
871 package (Liao et al., 2019). Generated count data were then used to identify differentially  
872 expressed genes using DESeq2 (Love et al., 2014). Genes with very low read counts were  
873 excluded. Finally, Gene Set Enrichment Analysis was performed using GSEA software (Mootha  
874 et al., 2003; Subramanian et al., 2005) on pre-ranked list generated by DESeq2.

875 To investigate the nature of cells eliminated by cell competition during early mouse embryogenesis  
876 by means of Single Cell RNA-Sequencing (scRNA-seq), early mouse embryos were dissected at  
877 E5.5 and cultured overnight in the presence or absence of caspase inhibitors. On the following  
878 morning, embryos were dissociated with Accutase and subjected to single-cell sorting into 384-  
879 well plate. Total RNA isolation was then carried out using a RNA extraction Kit (RNeasy Mini Kit,  
880 Qiagen). scRNA-seq was performed using the Smart-Seq2 illumina method. PolyA  
881 selection/enrichment with Ultra II Kit (NEB) was the method adopted for library preparation.

### 882 **Data processing, quality control and normalization**

883 We performed transcript quantification in our scRNA-seq data by running Salmon v0.8.2 (Patro et  
884 al., 2017) in the quasi-mapping-based mode. First, a transcriptome index was created from the  
885 mouse reference (version GRCm38.p4) and ERCC spike-in sequences. Then, the quantification  
886 step was carried out with the “quant” function, correcting for the sequence-specific biases (“--  
887 seqBias” flag) and the fragment-level GC biases (“--gcBias” flag). Finally, the transcript level

888 abundances were aggregated to gene level counts. On the resulting raw count matrix including  
889 1,495 cells, we apply a quality control to exclude poor quality cells from downstream analyses.  
890 For the quality control we used the following criteria: we identified the cells that have a log<sub>10</sub> total  
891 number of reads equal to or greater than 4, a fraction of mapped reads equal to or greater than  
892 0.8, a number of genes with expression level above 10 reads per million equal to or greater than  
893 3000 and a fraction of reads mapped to endogenous genes equal to or greater than 0.5. This  
894 resulted in the selection of 723 cells, which were kept for downstream analyses. Transcripts per  
895 million (TPM) normalization (as estimated by Salmon) was used.

### 896 **Identification of highly variable genes and dimensionality reduction**

897 To identify highly variable genes (HVG), first we fitted a mean-total variance trend using the R  
898 function “trendVar” and then the variance was decomposed into biological and technical  
899 components with the R function “decomposeVar”; both functions are included in the package  
900 “scran” (version 1.6.9 (Lun et al., 2016)).

901 We considered HVGs those that have a biological component that is significantly greater than zero  
902 at a false discovery rate (Benjamini-Hochberg method) of 0.05. Then, we applied further filtering  
903 steps by keeping only genes that have an average expression greater to or equal than 10 TPM  
904 and are significantly correlated with one another (function “correlatePairs” in “scran” package,  
905 FDR<0.05). This yielded 1921 genes, which were used to calculate a distance matrix between  
906 cells defined as  $\sqrt{(1-\rho)/2}$ , where  $\rho$  is the Spearman’s correlation coefficient between cells. A  
907 2D representation of the data was obtained with UMAP package (version 0.2.0.0 [https://cran.r-](https://cran.r-project.org/web/packages/umap/index.html)  
908 [project.org/web/packages/umap/index.html](https://cran.r-project.org/web/packages/umap/index.html)) using the distance matrix as input.

### 909 **Cell clustering**

910 To classify cells into different clusters, we ran hierarchical clustering on the distance matrix (see  
911 above; “hclust” function in R with ward.D2 aggregation method) followed by the dynamic hybrid  
912 cut algorithm (“cutreeDynamic” function in R package “dynamicTreeCut” ([https://CRAN.R-](https://CRAN.R-project.org/package=dynamicTreeCut)  
913 [project.org/package=dynamicTreeCut](https://CRAN.R-project.org/package=dynamicTreeCut)) version 1.63.1, with the hybrid method, a minimum cluster  
914 size of 35 cells and a “deepSplit” parameter equal to 0), which identified five clusters. Cells from  
915 different batches were well mixed across these five clusters (see Figure S1), suggesting that the  
916 batch effect was negligible.

### 917 **Identification of a single-cell trajectory in the epiblast**

918 We calculated a diffusion map (“DiffusionMap” function in the R package “destiny” version 2.6.2  
919 (Angerer et al., 2016) on the distance defined above on the epiblast cells from CI-treated embryos.  
920 The pseudotime coordinate was computed with the “DPT” function with the root cell in the winner  
921 epiblast cluster (identified by the function “tips” in the “destiny” package). Such pseudotime

922 coordinate can be interpreted as a “losing score” for all the epiblast cells from the CI-treated  
923 embryos.

924 We estimated the losing scores of the epiblast cells from DMSO-treated embryos by projecting  
925 such data onto the diffusion map previously calculated (function “dm\_predict” in the destiny  
926 package). Finally, for each of the projected cells, we assigned the losing score as the average of  
927 the losing scores of the 10 closest neighbours in the original diffusion map (detected with the  
928 function “projection-dist” in the destiny package).

### 929 **Differential gene expression analysis along the trajectory**

930 To identify the genes that are differentially expressed along the trajectory, first we kept only genes  
931 that have more than 15 TPM in more than 10 cells (this list of genes is provided in Supplementary  
932 Table 4); then, we obtained the log-transformed expression levels of these genes (adding 1 as a  
933 pseudo-count to avoid infinities) as a function of the losing score and we fitted a generalized  
934 additive model to them (R function “gam” from “GAM” package version 1.16.). We used the  
935 ANOVA test for parametric effect provided by the gam function to estimate a p-value for each  
936 tested gene. This yielded a list of 5,311 differentially expressed genes (FDR < 0.01).

937 Next, we looked for groups of differentially expressed genes that share similar expression patterns  
938 along the trajectory. To this aim, similarly to what we did when clustering cells, we calculated a  
939 correlation-based distance matrix between genes, defined as  $\sqrt{(1-\rho)/2}$ , where  $\rho$  is the  
940 Spearman’s correlation coefficient between genes. Hierarchical clustering was then applied to this  
941 matrix (hclust function in R, with ward.D2 method) followed by the dynamic hybrid cut algorithm  
942 (dynamicTreeCut package) to define clusters (“cutreeDynamic” function in R with the hybrid  
943 method and a minimum cluster size of 100 genes and a deepSplit parameter equal to 0). This  
944 resulted in the definition of four clusters, three of genes that decrease along the trajectory (merged  
945 together for the GO enrichment and the IPA analysis) and one of increasing genes (Figure S2D).  
946 IPA (QIAGEN Inc., <https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis>),  
947 was run on all genes differentially expressed (FDR < 0.01) along the trajectory from winner to loser  
948 cells (see Figures 2A-D and Figures 3A-C), using all the tested genes as a background (see  
949 Supplementary Table 4). This software generated networks, canonical pathways and functional  
950 analysis. The list of decreasing/increasing genes is provided in Supplementary Tables 1 and 2.

### 951 **Analysis of Mitochondrial DNA heteroplasmy**

952 We used STAR (version 2.7 (Dobin et al., 2013)) to align the transcriptome of the epiblast cells  
953 from CI-treated embryos (274) to the mouse reference genome (mm10). Only reads that uniquely  
954 mapped to the mitochondrial DNA (mtDNA) were considered. From these, we obtained allele  
955 counts at each mtDNA position with a Phred Quality Score greater than 33 using the samtools  
956 mpileup function.

957 Next, we applied filters to remove cells and mtDNA positions with a low coverage. First, we  
958 removed cells with fewer than 2,000 mtDNA positions covered by more than 50 reads. Second,  
959 we removed positions having less than 50 reads in more than 50% of cells in each of the three  
960 epiblast clusters (winner, intermediate and loser). These two filters resulted in 259 cells and 5,192  
961 mtDNA positions being considered for further analyses.

962 Starting from these cells and positions, we applied an additional filter to keep only positions with  
963 a sufficiently high level of heteroplasmy. To this aim, for each position with more than 50 reads in  
964 a cell, we estimated the heteroplasmy as:

$$965 \quad H = 1 - f_{max}$$

966 where  $f_{max}$  is the frequency of the most common allele. We kept only positions with  $H > 0.01$  in at  
967 least 10 cells.

968 Finally, using generalized additive models (see above), we identified the positions whose  
969 heteroplasmy  $H$  changes as a function of the cells' losing score in a statistically significant way.  
970 We found a total of eleven significant positions (FDR < 0.001), six of them in the *mt-Rnr1* gene  
971 and five in the *mt-Rnr2* gene. All of these positions have a higher level of heteroplasmy in loser  
972 cells (see Figure 6B-G and Figure S5F-K). The results remain substantially unaltered if the  
973 Spearman's rank correlation test (in alternative to the generalized additive models) is used.

974 For the barplot shown in Figure 6H and the correlation heatmaps in Figure 6I and S5L, we took  
975 into account only cells that covered with more than 50 reads all the significant positions in the *mt-*  
976 *Rnr1* gene (215 cells, Figures 6H and 6I) or in both the *mt-Rnr1* and *mt-Rnr2* genes (214 cells,  
977 Figure S5L).

978 As a negative control, we repeated the analysis described above using the ERCC spike-ins added  
979 to each cell. As expected, none of the positions was statistically significant, which suggested that  
980 our procedure is robust against sequence errors introduced during PCR amplification.

### 981 **Common features of scRNA-seq and bulk RNA-seq datasets**

982 Differential expression analysis between the co-cultured winner HB(24%) and loser cell line  
983 BG(95%) was performed using the package EdgeR version 3.20.9 (Robinson et al., 2010).

984 Batches were specified in the argument of the function `model.matrix`. We fitted a quasi-likelihood  
985 negative binomial generalized log-linear model (with the function `glmQLFit`) to the genes that were  
986 filtered by the function `filterByExpr` (with default parameter). These genes were used as  
987 background for the gene enrichment analysis.

988 We set a FDR of 0.001 as a threshold for significance. The enrichment analysis for both the  
989 scRNA-seq and bulk RNA-seq datasets were performed using the tool `g:Profiler` (Reimand et al.,  
990 2011). The list of up-regulated, down-regulated and background genes related to the DE analysis  
991 for the bulk RNA-seq dataset are provided in the Supplementary Tables 5, 6 and 7.

992 **Quantification and Statistical Analysis**

993 Flow cytometry data was analysed with FlowJo Software.

994 Western blot quantification was performed using Image Studio Lite (LI-COR). Protein expression  
995 levels were normalised to loading controls vinculin or  $\alpha$ -tubulin.

996 The quantification of the DDIT3 and OPA1 expression in embryos was done by two distinct  
997 methods. DDIT3 expression was quantified by counting the number of epiblast cells with positive  
998 staining in the embryos of each group. The expression of OPA1 was quantified on Fiji software as  
999 the mean fluorescence across a 10 pixel width line drawn on the basal cytoplasm of each cell with  
1000 high or low p-rpS6 fluorescence intensity, as specified in (Bowling *et al.*, 2018). A min of 8 cells  
1001 were quantified per condition (high vs low mTOR activity) in each embryo. Six embryos treated  
1002 with CI were analysed. Mean grey values of OPA1 fluorescence for each epiblast cell are pooled  
1003 on the same graph.

1004 The statistical analysis of the results was performed using GraphPad Prism v8 Software  
1005 (GraphPad Software, United States of America). Data was tested for normality using Shapiro-Wilk  
1006 normality test. Parametric or non-parametric statistical tests were applied accordingly. Details  
1007 about the test used in each of the experiments are specified in figure legends. Statistical  
1008 significance was considered with a confidence interval of 0.05%. n.s., non-significant; \*  $p < 0.05$ ; \*\*  
1009  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

1010 **Data and Code Availability**

1011 Data were analysed with standard programs and packages, as detailed above. Code is available  
1012 on request. Raw as well as processed data are available through ArrayExpress, accession  
1013 numbers E-MTAB-8640, for scRNA-seq data, and E-MTAB-8692, for bulk RNA-seq data.



## 1014 References


- 1015 Allio, R., Donega, S., Galtier, N., and Nabholz, B. (2017). Large Variation in the Ratio of  
1016 Mitochondrial to Nuclear Mutation Rate across Animals: Implications for Genetic Diversity and  
1017 the Use of Mitochondrial DNA as a Molecular Marker. *Mol Biol Evol* *34*, 2762-2772.
- 1018 Angerer, P., Haghverdi, L., Buttner, M., Theis, F.J., Marr, C., and Buettner, F. (2016). destiny:  
1019 diffusion maps for large-scale single-cell data in R. *Bioinformatics* *32*, 1241-1243.
- 1020 Bowling, S., Di Gregorio, A., Sancho, M., Pozzi, S., Aarts, M., Signore, M., M, D.S., Barbera,  
1021 J.P.M., Gil, J., and Rodriguez, T.A. (2018). P53 and mTOR signalling determine fitness selection  
1022 through cell competition during early mouse embryonic development. *Nat Commun* *9*, 1763.
- 1023 Bowling, S., Lawlor, K., and Rodriguez, T.A. (2019). Cell competition: the winners and losers of  
1024 fitness selection. *Development* *146*.
- 1025 Burgstaller, J.P., Johnston, I.G., Jones, N.S., Albrechtova, J., Kolbe, T., Vogl, C., Futschik, A.,  
1026 Mayrhofer, C., Klein, D., Sabitzer, S., *et al.* (2014). MtDNA segregation in heteroplasmic tissues  
1027 is common in vivo and modulated by haplotype differences and developmental stage. *Cell Rep*  
1028 *7*, 2031-2041.
- 1029 Burgstaller, J.P., Johnston, I.G., and Poulton, J. (2015). Mitochondrial DNA disease and  
1030 developmental implications for reproductive strategies. *Mol Hum Reprod* *21*, 11-22.
- 1031 Burr, S.P., Pezet, M., and Chinnery, P.F. (2018). Mitochondrial DNA Heteroplasmy and Purifying  
1032 Selection in the Mammalian Female Germ Line. *Dev Growth Differ* *60*, 21-32.
- 1033 Chen, H., Detmer, S.A., Ewald, A.J., Griffin, E.E., Fraser, S.E., and Chan, D.C. (2003).  
1034 Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for  
1035 embryonic development. *J Cell Biol* *160*, 189-200.
- 1036 Chinnery, P.F., and Hudson, G. (2013). Mitochondrial genetics. *Br Med Bull* *106*, 135-159.
- 1037 Claveria, C., Giovinazzo, G., Sierra, R., and Torres, M. (2013). Myc-driven endogenous cell  
1038 competition in the early mammalian embryo. *Nature* *500*, 39-44.
- 1039 Czechanski, A., Byers, C., Greenstein, I., Schrode, N., Donahue, L.R., Hadjantonakis, A.K., and  
1040 Reinholdt, L.G. (2014). Derivation and characterization of mouse embryonic stem cells from  
1041 permissive and nonpermissive strains. *Nat Protoc* *9*, 559-574.
- 1042 Di-Gregorio, A., Sancho, M., Stuckey, D.W., Crompton, L.A., Godwin, J., Mishina, Y., and  
1043 Rodriguez, T.A. (2007). BMP signalling inhibits premature neural differentiation in the mouse  
1044 embryo. *Development* *134*, 3359-3369.
- 1045 Diaz-Diaz, C., Fernandez de Manuel, L., Jimenez-Carretero, D., Montoya, M.C., Claveria, C.,  
1046 and Torres, M. (2017). Pluripotency Surveillance by Myc-Driven Competitive Elimination of  
1047 Differentiating Cells. *Dev Cell* *42*, 585-599 e584.
- 1048 Diaz-Diaz, C., and Torres, M. (2019). Insights into the quantitative and dynamic aspects of Cell  
1049 Competition. *Curr Opin Cell Biol* *60*, 68-74.
- 1050 Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M.,  
1051 and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* *29*, 15-21.
- 1052 Ellis, S.J., Gomez, N.C., Levorse, J., Mertz, A.F., Ge, Y., and Fuchs, E. (2019). Distinct modes  
1053 of cell competition shape mammalian tissue morphogenesis. *Nature* *569*, 497-502.
- 1054 Fan, W., Waymire, K.G., Narula, N., Li, P., Rocher, C., Coskun, P.E., Vannan, M.A., Narula, J.,  
1055 Macgregor, G.R., and Wallace, D.C. (2008). A mouse model of mitochondrial disease reveals  
1056 germline selection against severe mtDNA mutations. *Science* *319*, 958-962.
- 1057 Fischer, M. (2017). Census and evaluation of p53 target genes. *Oncogene* *36*, 3943-3956.
- 1058 Floros, V.I., Pyle, A., Dietmann, S., Wei, W., Tang, W.C.W., Irie, N., Payne, B., Capalbo, A.,  
1059 Noli, L., Coxhead, J., *et al.* (2018). Segregation of mitochondrial DNA heteroplasmy through a  
1060 developmental genetic bottleneck in human embryos. *Nat Cell Biol* *20*, 144-151.
- 1061 Freyer, C., Cree, L.M., Mourier, A., Stewart, J.B., Koolmeister, C., Milenkovic, D., Wai, T.,  
1062 Floros, V.I., Hagstrom, E., Chatzidaki, E.E., *et al.* (2012). Variation in germline mtDNA  
1063 heteroplasmy is determined prenatally but modified during subsequent transmission. *Nat Genet*  
1064 *44*, 1282-1285.
- 1065 Gorman, G.S., Chinnery, P.F., DiMauro, S., Hirano, M., Koga, Y., McFarland, R., Suomalainen,  
1066 A., Thorburn, D.R., Zeviani, M., and Turnbull, D.M. (2016). Mitochondrial diseases. *Nat Rev Dis*  
1067 *Primers* *2*, 16080.




- 1068 Haghverdi, L., Buttner, M., Wolf, F.A., Buettner, F., and Theis, F.J. (2016). Diffusion pseudotime  
1069 robustly reconstructs lineage branching. *Nature methods* *13*, 845-848.
- 1070 Hashimoto, M., and Sasaki, H. (2019). Epiblast Formation by TEAD-YAP-Dependent Expression  
1071 of Pluripotency Factors and Competitive Elimination of Unspecified Cells. *Dev Cell* *50*, 139-154  
1072 e135.
- 1073 Johnston, I.G., Burgstaller, J.P., Havlicek, V., Kolbe, T., Rulicke, T., Brem, G., Poulton, J., and  
1074 Jones, N.S. (2015). Stochastic modelling, Bayesian inference, and new in vivo measurements  
1075 elucidate the debated mtDNA bottleneck mechanism. *Elife* *4*, e07464.
- 1076 Kauppila, J.H.K., Baines, H.L., Bratic, A., Simard, M.L., Freyer, C., Mourier, A., Stamp, C.,  
1077 Filograna, R., Larsson, N.G., Greaves, L.C., *et al.* (2016). A Phenotype-Driven Approach to  
1078 Generate Mouse Models with Pathogenic mtDNA Mutations Causing Mitochondrial Disease. *Cell*  
1079 *Rep* *16*, 2980-2990.
- 1080 Khrapko, K., Coller, H.A., Andre, P.C., Li, X.C., Hanekamp, J.S., and Thilly, W.G. (1997).  
1081 Mitochondrial mutational spectra in human cells and tissues. *Proc Natl Acad Sci U S A* *94*,  
1082 13798-13803.
- 1083 Kim, D., Perte, G., Trapnell, C., Pimentel, H., Kelley, R., and Salzberg, S.L. (2013). TopHat2:  
1084 accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.  
1085 *Genome Biol* *14*, R36.
- 1086 Kojima, Y., Kaufman-Francis, K., Studdert, J.B., Steiner, K.A., Power, M.D., Loebel, D.A., Jones,  
1087 V., Hor, A., de Alencastro, G., Logan, G.J., *et al.* (2014). The transcriptional and functional  
1088 properties of mouse epiblast stem cells resemble the anterior primitive streak. *Cell Stem Cell* *14*,  
1089 107-120.
- 1090 Kon, S., Ishibashi, K., Katoh, H., Kitamoto, S., Shirai, T., Tanaka, S., Kajita, M., Ishikawa, S.,  
1091 Yamauchi, H., Yako, Y., *et al.* (2017). Cell competition with normal epithelial cells promotes  
1092 apical extrusion of transformed cells through metabolic changes. *Nat Cell Biol* *19*, 530-541.
- 1093 Kramer, A., Green, J., Pollard, J., Jr., and Tugendreich, S. (2014). Causal analysis approaches  
1094 in Ingenuity Pathway Analysis. *Bioinformatics* *30*, 523-530.
- 1095 Kucinski, I., Dinan, M., Kolahgar, G., and Piddini, E. (2017). Chronic activation of JNK JAK/STAT  
1096 and oxidative stress signalling causes the loser cell status. *Nat Commun* *8*, 136.
- 1097 Latorre-Pellicer, A., Lechuga-Vieco, A.V., Johnston, I.G., Hamalainen, R.H., Pellico, J., Justo-  
1098 Mendez, R., Fernandez-Toro, J.M., Claveria, C., Guaras, A., Sierra, R., *et al.* (2019). Regulation  
1099 of Mother-to-Offspring Transmission of mtDNA Heteroplasmy. *Cell Metab.*
- 1100 Lee, H.S., Ma, H., Juanes, R.C., Tachibana, M., Sparman, M., Woodward, J., Ramsey, C., Xu,  
1101 J., Kang, E.J., Amato, P., *et al.* (2012). Rapid mitochondrial DNA segregation in primate  
1102 preimplantation embryos precedes somatic and germline bottleneck. *Cell Rep* *1*, 506-515.
- 1103 Liao, Y., Smyth, G.K., and Shi, W. (2019). The R package Rsubread is easier, faster, cheaper  
1104 and better for alignment and quantification of RNA sequencing reads. *Nucleic Acids Res* *47*,  
1105 e47.
- 1106 Lima, A., Burgstaller, J., Sanchez-Nieto, J.M., and Rodriguez, T.A. (2018). The Mitochondria and  
1107 the Regulation of Cell Fitness During Early Mammalian Development. *Curr Top Dev Biol* *128*,  
1108 339-363.
- 1109 Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and  
1110 dispersion for RNA-seq data with DESeq2. *Genome Biol* *15*, 550.
- 1111 Ludwig, L.S., Lareau, C.A., Ulirsch, J.C., Christian, E., Muus, C., Li, L.H., Pelka, K., Ge, W.,  
1112 Oren, Y., Brack, A., *et al.* (2019). Lineage Tracing in Humans Enabled by Mitochondrial  
1113 Mutations and Single-Cell Genomics. *Cell* *176*, 1325-1339 e1322.
- 1114 Lun, A.T., McCarthy, D.J., and Marioni, J.C. (2016). A step-by-step workflow for low-level  
1115 analysis of single-cell RNA-seq data with Bioconductor. *F1000Res* *5*, 2122.
- 1116 Madan, E., Gogna, R., and Moreno, E. (2018). Cell competition in development: information from  
1117 flies and vertebrates. *Curr Opin Cell Biol* *55*, 150-157.
- 1118 Melber, A., and Haynes, C.M. (2018). UPR(mt) regulation and output: a stress response  
1119 mediated by mitochondrial-nuclear communication. *Cell Res* *28*, 281-295.
- 1120 Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver,  
1121 P., Carlsson, E., Ridderstrale, M., Laurila, E., *et al.* (2003). PGC-1alpha-responsive genes

- 1122 involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat*  
1123 *Genet* *34*, 267-273.
- 1124 Morata, G., and Ripoll, P. (1975). Minutes: mutants of drosophila autonomously affecting cell  
1125 division rate. *Dev Biol* *42*, 211-221.
- 1126 Mouchiroud, L., Houtkooper, R.H., Moullan, N., Katsyuba, E., Ryu, D., Canto, C., Mottis, A., Jo,  
1127 Y.S., Viswanathan, M., Schoonjans, K., *et al.* (2013). The NAD(+)/Sirtuin Pathway Modulates  
1128 Longevity through Activation of Mitochondrial UPR and FOXO Signaling. *Cell* *154*, 430-441.
- 1129 Munch, C. (2018). The different axes of the mammalian mitochondrial unfolded protein  
1130 response. *BMC Biol* *16*, 81.
- 1131 Nargund, A.M., Pellegrino, M.W., Fiorese, C.J., Baker, B.M., and Haynes, C.M. (2012).  
1132 Mitochondrial import efficiency of ATFS-1 regulates mitochondrial UPR activation. *Science* *337*,  
1133 587-590.
- 1134 Patro, R., Duggal, G., Love, M.I., Irizarry, R.A., and Kingsford, C. (2017). Salmon provides fast  
1135 and bias-aware quantification of transcript expression. *Nat Methods* *14*, 417-419.
- 1136 Prudent, J., and McBride, H.M. (2017). The mitochondria-endoplasmic reticulum contact sites: a  
1137 signalling platform for cell death. *Curr Opin Cell Biol* *47*, 52-63.
- 1138 Quiros, P.M., Mottis, A., and Auwerx, J. (2016). Mitonuclear communication in homeostasis and  
1139 stress. *Nat Rev Mol Cell Biol* *17*, 213-226.
- 1140 Quiros, P.M., Prado, M.A., Zamboni, N., D'Amico, D., Williams, R.W., Finley, D., Gygi, S.P., and  
1141 Auwerx, J. (2017). Multi-omics analysis identifies ATF4 as a key regulator of the mitochondrial  
1142 stress response in mammals. *J Cell Biol* *216*, 2027-2045.
- 1143 Rajasimha, H.K., Chinnery, P.F., and Samuels, D.C. (2008). Selection against pathogenic  
1144 mtDNA mutations in a stem cell population leads to the loss of the 3243A-->G mutation in blood.  
1145 *Am J Hum Genet* *82*, 333-343.
- 1146 Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome  
1147 engineering using the CRISPR-Cas9 system. *Nat Protoc* *8*, 2281-2308.
- 1148 Reimand, J., Arak, T., and Vilo, J. (2011). g:Profiler--a web server for functional interpretation of  
1149 gene lists (2011 update). *Nucleic Acids Res* *39*, W307-315.
- 1150 Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for  
1151 differential expression analysis of digital gene expression data. *Bioinformatics* *26*, 139-140.
- 1152 Sancho, M., Di-Gregorio, A., George, N., Pozzi, S., Sanchez, J.M., Pernaute, B., and Rodriguez,  
1153 T.A. (2013). Competitive interactions eliminate unfit embryonic stem cells at the onset of  
1154 differentiation. *Dev Cell* *26*, 19-30.
- 1155 Saveljeva, S., Cleary, P., Mnich, K., Ayo, A., Pakos-Zebrucka, K., Patterson, J.B., Logue, S.E.,  
1156 and Samali, A. (2016). Endoplasmic reticulum stress-mediated induction of SESTRIN 2  
1157 potentiates cell survival. *Oncotarget* *7*, 12254-12266.
- 1158 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch,  
1159 S., Rueden, C., Saalfeld, S., Schmid, B., *et al.* (2012). Fiji: an open-source platform for  
1160 biological-image analysis. *Nat Methods* *9*, 676-682.
- 1161 Sharpley, M.S., Marciniak, C., Eckel-Mahan, K., McManus, M., Crimi, M., Waymire, K., Lin, C.S.,  
1162 Masubuchi, S., Friend, N., Koike, M., *et al.* (2012). Heteroplasmy of mouse mtDNA is genetically  
1163 unstable and results in altered behavior and cognition. *Cell* *151*, 333-343.
- 1164 Smirnova, E., Griparic, L., Shurland, D.L., and van der Bliek, A.M. (2001). Dynamin-related  
1165 protein Drp1 is required for mitochondrial division in mammalian cells. *Mol Biol Cell* *12*, 2245-  
1166 2256.
- 1167 Snow, M.H. (1977). Gastrulation in the mouse: Growth and regionalization of the epiblast.  
1168 *Development* *42*, 293-303.
- 1169 Stewart, J.B., Freyer, C., Elson, J.L., Wredenberg, A., Cansu, Z., Trifunovic, A., and Larsson,  
1170 N.G. (2008). Strong purifying selection in transmission of mammalian mitochondrial DNA. *PLoS*  
1171 *Biol* *6*, e10.
- 1172 Stower, M.J., and Srinivas, S. (2018). The Head's Tale: Anterior-Posterior Axis Formation in the  
1173 Mouse Embryo. *Curr Top Dev Biol* *128*, 365-390.
- 1174 Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A.,  
1175 Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., *et al.* (2005). Gene set enrichment


1176 analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc  
1177 Natl Acad Sci U S A 102, 15545-15550.  
1178 Topf, U., Wrobel, L., and Chacinska, A. (2016). Chatty Mitochondria: Keeping Balance in  
1179 Cellular Protein Homeostasis. Trends Cell Biol 26, 577-586.  
1180 Yun, J., and Finkel, T. (2014). Mitohormesis. Cell Metab 19, 757-766.  
1181 Zhang, H., Burr, S.P., and Chinnery, P.F. (2018). The mitochondrial DNA genetic bottleneck:  
1182 inheritance and beyond. Essays Biochem 62, 225-234.  
1183 Zhao, Q., Wang, J., Levichkin, I.V., Stasinopoulos, S., Ryan, M.T., and Hoogenraad, N.J. (2002).  
1184 A mitochondrial specific stress response in mammalian cells. EMBO J 21, 4411-4419.  
1185 Zhou, W., Choi, M., Margineantu, D., Margaretha, L., Hesson, J., Cavanaugh, C., Blau, C.A.,  
1186 Horwitz, M.S., Hockenbery, D., Ware, C., *et al.* (2012). HIF1alpha induced switch from bivalent  
1187 to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition. EMBO J 31, 2103-  
1188 2116.  
1189

# Graphical Abstract





**Fig. 1****A****B****C****Clusters:**








- 1- Normal (winner) Epiblast (78 CI, 229 DMSO)
- 2- Extraembryonic Ectoderm (77 CI, 94 DMSO)
- 3- Intermediate (125 CI, 9 DMSO)
- 4- Loser Epiblast (71 CI, 0 DMSO)
- 5- Visceral Endoderm (16 CI, 24 DMSO)

**D****Conditions**


- DMSO-treated (356 cells)
- CI-treated (367 cells)




**E**


**Fig. 2**


**Fig. 3****A****B****C****D****E****F****G****H**




**Fig. 4**

**Fig. 5**

**Fig. 6**


**Fig. 7**







**Fig. S1****A****B**

Condition\Batch	1	2	3	4	5
CI-treated	136	105	86	16	24
DMSO	132	110	78	15	21

**C**


Cluster/Batch	1	2	3	4	5
1	147	81	57	7	15
2	45	65	44	7	10
3	46	34	35	13	6
4	23	18	21	2	7
5	7	17	7	2	7

**D**

**Fig. S2**

**Fig. S3**

**A**




**B**

Gene	FDR	Rank
<i>Ddit3</i>	4.63E-39	2
<i>Atf3</i>	6.08E-27	22
<i>Atf4</i>	2.14E-23	31
<i>Foxo3</i>	2.69E-22	37
<i>Ppp1r15a</i>	8.33E-18	68
<i>Eif2ak3</i>	7.17E-13	150
<i>Nfe2l2</i>	1.55E-10	207
<i>Gdf15</i>	5.53E-08	333


**C**

Gene	FDR	Rank
<i>Mthfd1l</i>	2.54E-35	147
<i>Hspe1</i>	8.71E-34	164
<i>Cat</i>	2.44E-30	219
<i>Hspd1</i>	6.93E-13	1262
<i>Sod2</i>	1.25E-10	1551
<i>Hsph1</i>	4.48E-10	1655
<i>Lonp1</i>	1.08E-06	2348
<i>Eif2a</i>	1.49E-06	2382
<i>Mthfd2</i>	1.31E-05	2693
<i>Hspa4</i>	2.84E-05	2790
<i>Cth</i>	2.53E-03	3677
<i>Nrf1</i>	2.86E-03	3698


**D**




**E**




**F**





**G**




**Fig. S4**




**Fig. S5**



**L** Spearman correlation of mutations within *mt-Rnr1* and *mt-Rnr2* from CI-treated (214 cells)




**Fig. S6**

**Fig. S7**

**A**

Source	Term	Adjusted p-value
GO:CC	mitochondrial protein complex	5.91E-05
GO:CC	inner mitochondrial membrane protein complex	8.84E-04
GO:CC	mitochondrial inner membrane	8.93E-04
GO:CC	mitochondrial respirasome	2.44E-03
GO:CC	respiratory chain complex	3.89E-03
GO:CC	respirasome	6.50E-03
GO:CC	mitochondrial part	1.06E-02
GO:CC	organelle inner membrane	4.65E-02
KEGG	oxidative phosphorylation	7.71E-04
KEGG	Huntington disease	2.35E-03
WP	electron transport chain	1.26E-03

**B**



**C**

